2013 Annual Report - University of Michigan Kellogg Eye Center

Transcription

2013
Annual Report
UNIVERSITY OF MICHIGAN W.K. KELLOGG EYE CENTER 2 013 ANNUAL REPORT
CURING
PREVENTING
TREATING
Looking to the Future of Ophthalmology
University of Michigan Kellogg Eye Center Annual Report 2013
2
5
13
20
26
Perspectives on the Future
of Ophthalmology
Sharing Wisdom on a
Global Basis
Discovering New Therapies
for Eye Disease
2 Moving towards curing,
8 Developing low vision and
16 Regenerating cells to restore
8 Sharing insights on quality
19 Investigating the potential
9 Leveraging efficiencies at the
20 Testing a new treatment
4 Personalizing care for
patients with chronic eye
diseases
Developing the Foundations
for Tomorrow’s Breakthroughs
Providing the Means to
Shape the Future
6 Using telemedicine to bring
10 Supporting high-risk, high-
23 Fostering a learning
treating, and preventing
eye disease
Meeting the Need for Eye
Care in the Era of Population
Health
eye care to patients where
they live
7 Improving our quality on
a continuous basis
*This report covers the period
July 1, 2012, through June 30, 2013
contact lens expertise in Taiwan
of care
Aravind Eye Care System
reward, early-stage research
12 Creating “audacious” goals
for vision research
13 Nurturing tomorrow’s leaders
14 Studying mechanisms of
vision and disease
function
for reprogramming cells
for Graves’ eye disease
environment for tomorrow’s
leaders
24 Gathering leaders at a
symposium on gene and
stem-cell based therapies
for retinal disease
26 Inaugurating the Frueh
Professorship
Front cover: Top row: Ryan Fante, M.D., Stephanie Chu, M.D., Jennifer Weizer, M.D. Bottom row: Maho Shibata, M.D., Ph.D., Jason Miller, M.D., Ph.D.
Back cover: Top row: Lindsey De Lott, M.D., Philip Gage, Ph.D. Bottom row: Julia Richards, Ph.D., Rajesh Rao, M.D.
Kellogg’s leadership team: Paul Lee, M.D., J.D., Thomas Gardner, M.D., M.S., Alan Sugar, M.D., Michael Smith-Wheelock, M.D., Shahzad Mian, M.D.
The Chair’s Perspective
Keeping Our Eyes
on the Future
We are fortunate to be part of the University of
Michigan and its Health System, whose leaders place
great value on discovery and innovation. Within our
Department and across the Michigan campus, forwardlooking thinkers are taking a new look at how we care
for our patients, educate our trainees, and accelerate
exciting new areas of research.
This year’s annual report offers a glimpse at some
of the advances we believe will significantly contribute
to the future of ophthalmology. Our growing faculty is
leading us in new directions with collaborative initiatives in areas such as telemedicine, vision regeneration, delivery models influenced by best practices from
around the world, and new training approaches.
Applying technology to health care. When we
follow traditional models of care focusing on “one
size fits all” solutions, we miss opportunities to deliver
personalized health strategies to help patients at earlier
stages of disease when the payoff may be greater. For
2
university of michigan kellogg eye center
example, the risk of vision loss is high when patients
are not able to follow instructions for taking glaucoma
medications. To help mitigate this issue, Dr. Paula Anne
Newman-Casey, along with colleagues from the School
of Public Health, the VA’s Health Services Research
Group, the Institute for Health Policy and Innovation,
and the College of Pharmacy, is investigating the use of
personalized educational technologies to help patients
manage their medications over a lifetime. Other faculty,
like Drs. Maria Woodward and Lindsey De Lott, see
telemedicine as a means to extend the reach of specialty
care for patients who live far from medical centers
where complex ophthalmic conditions are often treated.
With increasing interest in the health of populations as
a whole, such approaches will help maintain high quality care for individuals as well as for groups.
Encouraging our colleagues to pursue their
interests. Our new residency career development
awards encourage trainees to initiate and conduct research and academic projects they are passionate about,
providing them with the opportunity to be leaders, with
support and mentoring from experienced scientists.
In this report, we highlight three of the six awardees’
projects: a survey of safety standards established by the
United Kingdom’s National Health System, a study of
protein changes that occur in various types of macular
edema, and an investigation of the feasibility of using
the femtosecond laser for glaucoma surgery.
Kellogg also emphasizes training and mentoring
for our early career clinician-scientists. Dr. Thomas
Gardner led the Department’s effort to obtain a
National Eye Institute K12 Training Grant that provides
protected research time and mentoring for faculty who
wish to develop a major research program in tandem
with their practice. In addition to our two K12 faculty,
four more Kellogg faculty have received individual NIH
clinician-scientist training awards this past year. Our
patients will benefit from having doctors who are able
to connect their research efforts with patient problems
observed in the clinic.
Dr. Robin Ali, noted for his work in gene and cell-based
therapies, will become a Visiting Professor at Kellogg,
sharing his knowledge with faculty and trainees in our
Department. And we continue to cultivate relationships
with other leaders from institutions worldwide.
Friends of the Eye Center are helping us find new
ways to support novel ideas. Many generous donors
have contributed to the Paul R. Lichter, M.D., Research
Discovery Fund to provide seed funding for innovative,
high-risk, high-reward research. This support allows
scientists to test potentially revolutionary new ideas and
to collect data needed to ultimately translate these ideas
into improved patient care. Over the years, our friends
have been steadfast supporters of our research program
and our Department.
Ophthalmology is a global enterprise. We are learning from colleagues in other countries, while providing
unique training opportunities here at Kellogg. A team
comprised of members from Kellogg, U-M, Aravind,
The patient is the center of our world. Any conand Dr. Alan Robin, the first Visiting Scholar to our
cept — from telemedicine to gene therapy — must
Center for International Ophthalmology, worked with
translate to improved and compassionate care for our
U-M medical student Hong-Gam Le to better underpatients. In this report, you can read
stand the uniquely efficient process
“The future of eye care
about Drs. Terry Smith and Raymond
for cataract surgeries at the Aravind
Douglas’ success in launching a large
Eye Hospitals in India. Back in our
is full of promise, thanks
clinical trial to evaluate a treatment
clinics, the Center has arranged for
for Graves’ eye disease that is the
physicians from other countries to
to the shared goals and
direct result of their years of research
receive training in low vision and speon this autoimmune disorder. Their
cialty contact lens care.
efforts of our faculty,
patients who struggle with this difAdvancing new fields of research.
staff, alumni, and friends ficult disease are grateful for their
progress.
For years, physicians have strived
From our vantage point, the
for the day we could offer patients
of the Eye Center.”
future of eye care is full of promise,
targeted, customized treatments, such
thanks to the shared goals and efforts
as gene and stem-cell based thera— Paul P. Lee, M.D., J.D.
of our faculty, staff, alumni, and
pies. Our scientists are bringing these
friends of the Eye Center. Together we are summoning
hopes closer to reality, with their progress in regenerathe best of our innovative and sometimes “audacious”
tive medicine through the study of eye development
thinking to improve lives by curing, treating, and preand eye tissue regeneration. One of our newest faculty
venting eye disease. As you read about the achievements
members, Dr. Rajesh Rao, is investigating the concept
and activities in this report, I hope that you will be
of reprogramming cells to repair diseased eye tissue.
inspired by the dedication of all who contribute to the
And recently, our research faculty met with other leadKellogg Eye Center.
ing scientists at an international symposium to discuss
strategies for moving advanced therapies for eye disease
forward into clinical trials.
Collaborating for innovation. New ideas often
come from working with colleagues in other disciplines
and with other institutions. Our faculty has initiated
collaborative projects with a range of programs including engineering, rheumatology, and mathematics.
Paul P. Lee, M.D., J.D.
F. Bruce Fralick Professor and Chair
Ophthalmology and Visual Sciences
Director, W.K. Kellogg Eye Center
Innovation in vision
3
Health Information
Technology Helps
Personalize Eye
Care
Dr. Newman-Casey wants to make it easier for
every patient to adhere to medication regimens
Paula Anne Newman-Casey, M.D. (third from left) with her mentorship team:
Michele Heisler, M.D., M.P.H., Joshua Stein, M.D., M.S., Lawrence An, M.D.,
Karen Farris, Ph.D., and Paul Lee, M.D., J.D.
into consideration patient perceptions about their
“Medications have been shown to stop the progression
disease and its treatment. “We want to impact not only
to blindness in glaucoma, but their effectiveness is often
medication adherence, but also self-efficacy — in helping
decreased by poor adherence,” says assistant professor
patients to have the confidence to successfully take
Paula Anne Newman-Casey, M.D., M.S. “Research has
their medication regularly,” says Dr. Newman-Casey.
shown that at least 30 percent of glaucoma patients do
Dr. Newman-Casey will
not adhere to their daily medicollaborate with experts at the
cation schedules.” The same
“As physicians, we are trying to
U-M Center for Health Commuproblem occurs in many chronic
convince our patients to do some- nication Research to bring their
diseases.
expertise into the realm of eye
“One of the unique chalthing
that
disrupts
their
daily
care. “The Center has created a
lenges of glaucoma therapy
wide range of educational prois that patients do not always
routine
—
all
without
any
immegrams using innovative models
know how to properly instill
of technology to improve chrondrops into their eyes,” says Dr.
diate benefit or gain — so that
ic disease management in such
Newman-Casey. “Added to this,
areas as smoking cessation and
most of these medications are
ten to twenty years from now
diabetes, but these programs are
administered on a daily basis,
rarely used in ophthalmology,”
often twice a day. As physicians, they will still have good vision.”
says Dr. Newman-Casey. “Our
we are trying to convince our
long-term goal is to develop
patients to do something that
— Paula Anne Newman-Casey, M.D., M.S.
additional tools with health
disrupts their daily routine — all
information technology to improve chronic disease
without any immediate benefit or gain — so that ten to
management and outcomes in ophthalmology.”
twenty years from now they will still have good vision.
This is one of the reasons that adherence rates are low.
Dr. Newman-Casey joined the Department of OphWe’re talking about long-term benefit, but with a great
thalmology and Visual Sciences under the National
deal of short-term cost.”
Eye Institute K12 Michigan Vision Clinician-Scientist
Under a training grant from the National Eye
Development Program, an award that provides training
Institute, Dr. Newman-Casey plans to create technoland mentorship to young ophthalmologists planning to
ogy-based educational programs that could make it
develop careers as clinician-scientists. The Department
simpler for patients to follow their medication regiis one of only six in the nation to receive this award.
mens. Such interventions will be personalized and take
4
Helping
Patients
with neuro-ophthalmic disorders
receive the care they need
Dr. De Lott will analyze patterns of care
with an eye toward telemedicine solutions
One of Kellogg’s newest faculty members wants to
improve care for patients with neuro-ophthalmic
Dr. Lindsey De Lott’s research will help patients with neuro-ophthalmic conditions.
conditions. Lindsey B. De Lott, M.D., who completed
On her computer screen is an image of severe papilledema, swelling of the
her residency in neurology and a fellowship in neurooptic disc caused by increased intracranial pressure.
ophthalmology, has observed that non-specialists are
often the first to see patients with neuro-ophthalmic
diseases. As such, one of her goals is to help our coldatabases that meticulously detail patient visits to clinics
leagues make faster diagnoses and promote appropriate
and hospital emergency rooms, Dr. De Lott will analyze
testing and care.
the number of patient visits, types of providers caring
Part of the challenge lies with the complexity of
for these patients, diagnoses rendered, testing ordered,
these disorders, often the result of neurologic conditions
and how these parameters are changing over time. That
affecting the visual pathways, such as stroke or trauinformation, along with geographic
matic brain injury. Specific disorders
data, will allow her to evaluate how
are not easy to diagnose, given the ar- Dr. De Lott envisions telecare may differ in certain areas,
ray of symptoms, from headache and
particularly in regions where there
blurred vision to double vision.
medicine applications to
is little neuro-ophthalmic support.
“The situation is further comhelp providers identify
The resulting report will provide
plicated when patients do not have
the basis for developing new proaccess to specialty care,” says
grams to aid physicians in the triage,
Dr. De Lott. “Neuro-ophthalmologists and treat common neurodiagnosis, and management process.
tend to practice in academic medical
ophthalmic conditions and Dr. De Lott envisions telemedicine
centers or in big cities, which means
applications to help providers identhat patients in rural areas or some
to improve patient access
tify and treat common neuro-ophurban areas may have more difficulty
thalmic conditions and to improve
receiving advanced care.”
to specialty care.
patient access to specialty care.
Dr. De Lott has been awarded
“These kinds of applications
a National Institutes of Health T32
could also help us make more effective use of reTraining Grant from the U-M Department of Neusources,” says Dr. De Lott. “But most important, we
rology to investigate where patients are first seen for
can help patients by providing quality care whether
neuro-ophthalmologic conditions and how that affects
they live in this country or anywhere in the world.”
resource utilization. Drawing on two large national
5
Dr. Maria Woodward shows resident Courtney Kauh, M.D., how to capture photos
of the exterior features of eye disease using a portable camera.
The resulting image of the eye could be sent electronically to
a physician in another location.
Telemedicine to Extend Eye Care
in the Era of Information Technology
Patients who lack access to health care will benefit most from new technologies
a geographically distant clinic and a physician, with
Over the next five years, cornea specialist Maria A.
images and other data sent via telecommunication
Woodward, M.D., will investigate how telemedicine
technology. Given the growing number of people with
can be used to extend affordable and accessible eye
cell phones and their increasing comfort with all kinds
care to individuals in underserved communities. This
of electronic communications, Dr. Woodward believes
technology will also improve care by allowing providers
that, with proper training, medito detect eye conditions earlier
cal staff and patients could capin their course. Dr. Woodward
“Validating telemedicine for
ture usable images of corneal
has been awarded a National
and external eye diseases. “The
Institutes of Health K23 grant
eye diseases is critical so we
technology is here today — and
for her research project entitled,
Telemedicine for Anterior Eye
maintain the highest standards it will only get better,” she says.
The focus of the work is
Diseases.
According to the National
of patient care while moving in to not only validate the ability
of telehealth to promote highEye Institute (NEI), the majority
quality care, but to also develop a
of visits to eye care providers nathe ‘digital’ health care era.”
system to implement care that can
tionally are the result of diseases
— Maria A. Woodward, M.D.
be directed by ophthalmologists.
that affect the anterior, or front
“Validating telemedicine for
part of the eye, such as cataract
eye diseases is critical so we maintain the highest stanor corneal diseases. While the NEI has emphasized
dards of patient care while moving in the ‘digital’ health
the need to develop telemedicine technologies to
care era,” says Dr. Woodward.
diagnose and monitor patients with eye diseases from
Once developed, high quality teleheath systems
afar, less attention has been focused on anterior
will help prevent a shortage of eye care services as our
segment conditions.
population grows and ages.
Telemedicine, telehealth, and e-health generally
refer to the sharing of medical information between
6
Improving
Patient Care
is no small measure
Kellogg works to ensure quality care
at the local, state, and national levels
Dr. Jennifer Weizer is leading Kellogg’s initiative to report on quality of care.
care for our patients.”
In the public debate on health care, pundits and patients
At the state level, Dr. Weizer is leading the Collabare talking more and more about quality of care. But
orative Glaucoma Quality Initiative (CGQI), a study
what does “quality” mean and how can it be measured?
to report and improve how physicians follow glauThe University of Michigan Kellogg Eye Center is concoma patient visit guidelines provided by the American
tinuously collecting data to help patients better underAcademy of Ophthalmology (AAO). If physicians can
stand the indicators of quality eye care.
improve how well they follow these guidelines, they
Under the leadership of Jennifer S. Weizer, M.D.,
could help delay the progression of glaucoma and thus
associate professor and glaucoma specialist, Kellogg
improve outcomes, quality of life,
has measured its performance for
nearly ten years. In partnership with “We measure our outcomes and reduce health care costs.
For the CGQI, Kellogg is
the University of Michigan Health
partnering
with the Grand Traverse
System’s Quality and Safety group,
quarterly and then share
Ophthalmology Clinic and the
Kellogg recently published its first
set of quality outcome measures,
the results with our faculty. Henry Ford Department of Ophthalmology to look at new glauincluding rates of unplanned reopThis information helps us to coma patient visits. Each group
erations, postoperative infections,
reviews and records — on a checkand success of specific procedures.
improve how we teach our
box form void of patient informaThese data measure the quality
tion — whether these visits included
of care for all patients treated for
residents and how we care
the major exam aspects recomspecific eye diseases (e.g., cataracts,
mended by AAO guidelines. Results
retinal detachment, and strabismus)
for our patients.”
will then be compiled, averaged,
and for those who have had eye
and reported back to the groups.
surgery (such as corneal transplants; — Jennifer S. Weizer, M.D.
Nationally, Dr. Weizer is a
and glaucoma, retinal, refractive
member of the AAO’s Registry Measure Development
and oculoplastic surgery) at Kellogg.
Workgroup, which is using electronic health records
Only a few ophthalmology departments in the
to develop the nation’s first comprehensive eye disease
country have such an extensive program, making
clinical database — the Intelligent Research in Sight
Kellogg a leader, at both the state and national
(IRIS) Registry. IRIS will report data to help validate
levels, in measuring and improving patient care.
the quality of care provided by ophthalmologists and
“Our program is broad and deep in that it
highlight areas for improvement — all with the goal of
covers all of our subspecialties, which is unusual for
improving the delivery of eye care.
ophthalmology departments,” says Dr. Weizer. “We
measure our outcomes quarterly and then share the
Kellogg outcomes are online at www.uofmhealth.org/
results with our faculty. This information helps us
quality-safety
to improve how we teach our residents and how we
7
Dr. Stephanie Chu in Kellogg's Low Vision Clinic.
Dr. Alan Robin meets with young physicians from the Robert Wood Johnson
Foundation Clinical Scholars Program at Michigan.
Global Ophthalmology
Kellogg Center for International Ophthalmology fosters the
exchange of knowledge and best practices globally
Kellogg Faculty Develop Training Programs
for International Physicians
Stephanie Chu, M.D., National Taiwan University
Hospital, was the first international physician to complete a new course on specialty contact lens fitting offered at the Kellogg Eye Center. The course was
developed by clinical instructor Sherry H. Day, O.D.,
and thirteen other faculty members.
“I was fortunate to spend two months at the
Kellogg Eye Center. My overall experience was outstanding,” says Dr. Chu. “During my stay, I studied
comprehensive contact lens fitting and low vision assessment. This helped me to understand the long-term
results of a variety of specialty lenses, and will assist
me in handling difficult ocular surface diseases or postsurgical corneal conditions.”
While at Kellogg, Dr. Chu was introduced to new
low vision aids and low vision services offered in the
United States. “I was impressed with the efficiency
and collaboration between social workers and medical
professionals in this area who combined their resources
to help visually-impaired patients,” says Dr. Chu.
8
Dr. Chu also had the opportunity to observe
Kellogg’s residency training program. “The program
is flexible and accommodating to the needs of residents—providing an abundance of resources such as
lectures, clinics, and surgical procedures,” says Dr. Chu.
Based on the model she observed at Kellogg, Dr. Chu
will make recommendations on modifying the resident
training program at the National Taiwan University
Hospital.
Kellogg Resident Compares
Ophthalmic Quality Measures
As the United States evaluates how it
delivers health care, there are lessons
to be learned from the United Kingdom’s long-standing National Health
System (NHS) and, specifically, from
the Royal College of Ophthalmologists (RCOphth).
Monica Michelotti, M.D., a second-year resident,
recently completed a research rotation at the Royal
Bolton Hospital (RBH) in Bolton and Moorfields Eye
Hospital (MEH) in London. She conducted a compara-
Hong-Gam Le (second from left) with Aravind Eye Hospital managers
R. Ushalini, MBA; A. Shobana, B.Sc., PGDHM; and R. Anjana Deep, MBA.
tive analysis of health care delivery systems in the U.K.
and the U.S. through the prism of ophthalmology.
Dr. Michelotti collaborated with Simon P. Kelly,
MB BCh, one of the U.K.’s leading specialists on quality
and safety in ophthalmology. She also studied patient
safety and quality assurance with Declan W. Flanagan,
MB BCh, medical director at MEH. Dr. Michelotti
reviewed the World Health Organization’s universal
checklist for safer surgery, and compared quality measures in different countries. She will present her work
at the upcoming World Association of Eye Hospitals
meeting at Aravind.
“This rotation allowed me to focus on research that
could help shape the future of health care,” says Dr.
Michelotti. Her work comparing existing standards and
measures of quality of care among ophthalmology units
around the world will help harmonize these standards
and accelerate our ability to determine what works best
for patients.
U-M Team Works with Aravind to Assess
Cataract Surgery
Under the guidance of Kellogg glaucoma specialist
Joshua D. Stein, M.D., M.S., and colleagues from
Aravind and Michigan, second-year medical student
Hong-Gam Le compared the Aravind Eye Hospitals’
high-volume, high-quality, low-cost system of cataract
surgery with ours.
Dr. Joshua Stein and Hong-Gam Le review data on cataract surgery.
Ms. Le completed an eight-week research rotation
at the Aravind Eye Hospitals in both Madurai and
Pondicherry, India, jointly sponsored by the U-M Medical School Student Biomedical Research Program and
the Kellogg Center for International Ophthalmology. By
taking a detailed clinical, work-flow, and resource-based
perspective, the study team suggested how we might
make our system of cataract surgery more efficient.
Center Collaborates with First Visiting Scholar
Alan L. Robin, M.D., Professor of Public Health and
Ophthalmology of the Bloomberg School of Public
Health and the Wilmer Eye Institute, Johns Hopkins
University, is collaborating with the Kellogg Center for
International Ophthalmology to address vision problems in the United States and abroad. “We are working
with the Aravind Eye Care Hospital in Tamil Nadu,
India, and the Tilganga Eye Hospital in Kathmandu,
Nepal, to develop systems, through telemedicine, to
screen with high sensitivity and specificity individuals at
early stages of glaucoma, so that we can prevent needless blindness,” says Dr. Robin, the first Visiting Scholar
to the Center for International Ophthalmology. “Strategies that we develop together with Michigan and our
global partners might well be used in both developing
nations and in underserved areas of our countries such
as big cities or rural sections of America.”
9
To fuel new ideas in vision research: The Paul R. Lichter, M.D.,
Research Discovery Fund
Thanks to dedicated contributors,
endowment exceeds initial goal
and keeps growing
When an ophthalmologist imagines a new approach
to solving a patient’s eye problem or a scientist begins
to follow a discovery in an unintended direction, that’s
where progress begins — but only if the resources are
in place to test whether the hunch has potential.
“The process for developing a research project that
can advance treatments for eye disease starts with gathering data and studying the initial idea,” says Paul R.
Lichter, M.D. “So it is imperative that we support
innovation at its earliest stages. Then the project can
compete for traditional funding. But it has to get that
far. We don’t want to leave any good ideas behind.”
10
Endowed funds that are part
of the Paul R. Lichter, M.D.,
Research Discovery Fund:
Thomas W. Breakey and Rutger W. Breakey
Ophthalmic Research Fund
Robert W. and Lynn H. Browne
Glaucoma Research Fund
Paul R. and Carolyn R. Lichter
Glaucoma Research Fund
Mary L. and Brian P. Campbell
Colette J. and Albert F. Kessel
Joel S. Mindel, M.D., Ph.D., and
Susan Weis Mindel
Oliver Family
Edward Berger
Endowed Research Fund
That’s the purpose of the Paul R. Lichter, M.D.,
Research Discovery Fund, which is providing grants
to faculty whose early-stage work has the potential to
advance vision science. The first round of grants will
be distributed in early 2014.
The Fund, which has topped more than $4 million
in gifts and pledges, was created in honor of Dr. Lichter
when he stepped down as chair of the Department of
Ophthalmology and Visual Sciences in 2012, a post he
held for 34 years. He is also the Founding Director of
the W.K. Kellogg Eye Center, which was established
under his leadership in 1985. During his tenure,
Dr. Lichter built a robust, world-class vision research
program.
Detroiter Makes Lasting Gift
to Vision Research
Edward Berger, a native Detroiter who worked
for the city in tax collections, was the last of four
siblings, three of whom never married. None
had children.
“He survived all of his siblings, and his assets grew as a result,” explains Jon B. Gandelot,
a Grosse Pointe Farms attorney who assisted Mr.
Berger with his estate plans. “He suffered from
age-related macular degeneration, and supporting
the Kellogg Eye Center struck a chord with him.”
When Mr. Berger passed away in 2012,
Mr. Gandelot had U-M establish the Edward Berger
Endowed Research Fund, part of the Paul R. Lichter,
M.D., Research Discovery Fund. A portion of the
estate was also designated for Alzheimer’s disease
research at U-M.
“Ed wanted to leave a legacy,” Mr. Gandelot
says. He wanted to make sure that the world was
better off as a result of him being here.”
“It means a great deal to me that this Fund will
ensure the future of such important work, and I am
grateful for the wide support it has received,” says
Dr. Lichter.
Contributors to the Fund include patients, alumni,
colleagues, friends, and family, as well as Dr. Lichter
and his wife, Carolyn. The Lichter Discovery Fund also
serves as an umbrella fund for named endowments that
share its goals (see list above). The Kellogg Eye Center
has committed to making the Lichter Discovery Fund an
ongoing fundraising priority due to our commitment to
supporting high-reward, high-risk research.
11
The 10 recipients of Audacious Goals in Vision Research awards. Back row: Russell Van Gelder, M.D., Ph.D., University of Washington; Jeffrey Stern, M.D., Ph.D.,
Regenerative Research Foundation, Rensselaer, NY; Robert Duvoisin, Ph.D., Oregon Health & Science University; Julia Richards, Ph.D., University of Michigan;
Steven Pittler, Ph.D., University of Alabama at Birmingham; Rajesh Rao, M.D., Washington University in St. Louis, currently, University of Michigan.
Front row: Paul Sieving, M.D., Ph.D., Director, National Eye Institute; Yingbin Fu, Ph.D., University of Utah; Janey Wiggs, M.D., Ph.D.,
Massachusetts Eye and Ear Infirmary; Tonia Rex, Ph.D., Vanderbilt University; Dennis Clegg, Ph.D., University of California, Santa Barbara.
Kellogg Scientists Offer “Audacious” Ideas
to advance national vision research
By winning awards from the National Eye Institute
(NEI), Kellogg scientists Rajesh C. Rao, M.D., and
Julia E. Richards, Ph.D., are helping to set the national
vision research agenda.
In 2013, the NEI challenged scientists from around
the world to develop ideas that would help steer vision
research for the future. Proposals from Drs. Rao and
Richards for the Audacious Goals in Vision Research
competition were two of only 10 selected from several
hundred submissions.
The winning proposal from Dr. Rao — who won
the award during his vitreoretinal surgery fellowship at
Washington University in St. Louis before joining the
Kellogg faculty in 2013 — is Reprogramming the Retina.
His research involves reprogramming easy-to-isolate
skin or blood cells and transplanting them into the
retina as well as reprogramming surviving retinal cells
into specific cell types to replace those that are damaged.
“Kellogg — and the University as a whole — are
great places to pursue this work because of their interest
in regenerative medicine, their collaborative environment, and their expertise with epigenetics and stem
cells,” he says.
12
Dr. Richards, the Harold F. Falls Collegiate
Professor of Ophthalmology and Visual Sciences
and professor of epidemiology in the U-M School
of Public Health, won for her proposal, Fountains
of Youth for the Eye.
Serious late-onset problems like macular degeneration and glaucoma result from a complex combination
of many different genetic and environmental risk factors. Dr. Richards proposes that instead of developing
multiple treatments targeting many complex causes,
we could delay onset of these diseases by intervening
in the one thing the diseases have in common — the
aging process.
“The interconnection of clinical and basic sciences
at Kellogg offers an excellent environment for the
evolution of interdisciplinary ideas,” she says.
The NEI drew from the 10 winning proposals to
develop one single goal — regenerating neurons and
neural connections in the eye and visual system — along
with two high-priority research areas — molecular
therapy for eye disease and the intersection of aging
and biological mechanisms of eye disease.
Awards for Resident Research
Grant allows residents to pursue research that sparks their interest
Ryan Fante, M.D.
Now in its second year, the Michigan Ophthalmology
Trainee Career Development Award (MOTCDA) has
provided six residents with the opportunity to pursue
research projects that spark their interest. Read about
two of our winners for the 2013–14 academic year.
Ryan J. Fante, M.D., third-year resident, received grant
funding for his research on macular edema (ME), or
swelling in the back of the eye, that can be the result of
diabetes or radiation treatment. Dr. Fante is working to
better understand the protein changes that accompany
different types of ME and to identify potential new
therapeutic targets. He also plans to characterize the
normal and pathologic composition of the vitreous in
various disease states. The vitreous is thought to contain
signaling molecules that lead to ME or are markers for
response to certain treatments for this condition.
“The MOTCDA is an award that provides support
for residents who are aspiring clinician-scientists,” says
Dr. Fante. “In this case, it provided the funding to initiate a basic science project to develop some of my ideas
about diabetic retinopathy. The unique collaboration
between our ophthalmology department and the medical school also allowed us to run assays that would not
have otherwise been possible.”
Ira Schachar, M.D., M.Sc.
Ira H. Schachar, M.D., M.Sc., third-year resident,
received grant funding for his research on the use of the
femtosecond laser for glaucoma treatment. Open-angle
glaucoma is characterized by high intraocular pressure
(IOP). When topical medications and laser trabeculoplasty have been ineffective in lowering IOP, the next
step is typically surgery directed at the anterior chamber of the eye. Clinician-scientists work to find alternatives to minimize surgical complications and maintain
lower IOP in the long term.
Dr. Schachar's research assessed if the femtosecond
laser is an effective alternative for glaucoma surgery.
“The opportunity to collaborate with the U-M
College of Engineering through MOTCDA has taken
this project from an idea to a reality,” says Dr.
Schachar. “With preliminary work from the MOTCDA
funding, we have applied for a larger developmental
grant aimed at understanding how best to use this
technique.”
Read about the MOTCDA award of second-year
resident Monica Michelotti, M.D., on page 8.
13
Support for interdepartmental collaboration and innovative training models drew Dr. Miller to the University of Michigan.
What happens when aging retinal cells stop
“Taking Out the Trash?”
Live-cell imaging techniques could
reveal where disruptions occur
One of Kellogg’s newest postdoctoral fellows is using
live-cell imaging techniques to understand what happens
when the retinal pigment epithelium (RPE) falls down
on its job of removing waste from the retina.
Photoreceptors shed 10 percent of their outer segments every day, which are then engulfed and digested
by the RPE. The breakdown products are either recycled
back to the photoreceptors or disposed of via another
layer of the eye, the choroid. A single RPE cell carries
out this waste disposal function day-in and day-out;
however, as the cell ages, its ability to handle the
“trash” diminishes, resulting in the accumulation of
fatty waste byproducts (lipofuscin and drusen). The
RPE’s declining function likely plays a major role in
dry age-related macular degeneration (AMD), a leading
cause of vision loss.
Postdoctoral fellow Jason M. Miller, M.D., Ph.D.,
is investigating which steps in this disposal process are
disrupted as the RPE ages. Dr. Miller’s research includes
14
the use of automated live-cell imaging techniques first
developed in his graduate lab at the University of
California, San Francisco. A long-term goal of his
research at Kellogg is to identify drugs that improve
the recycling capacity of the RPE, which then could be
developed as therapeutic candidates for dry AMD.
Dr. Miller, who conducts research in the labs of
Kellogg’s Debra A. Thompson, Ph.D., and David N.
Zacks, M.D., Ph.D., will collaborate with new U-M
faculty member Sami J. Barmada, M.D., Ph.D., assistant
professor of neurology, who shares expertise in advanced microscopy techniques.
Among the reasons he chose to pursue research at
Michigan, says Dr. Miller, is the University’s degree of
interdepartmental collaboration and support of young
faculty members. “However,” he adds, “it was the
ophthalmology department’s wholehearted embrace of
innovative training models, supporting academic interests ranging from education to policy to international
development to engineering to basic research, that made
Kellogg singularly unique for a young physician-scientist
such as myself.”
S t u d y i n g abnormal growth
of retinal blood vessels in eye complications of diabetes
Donald G. Puro, M.D., Ph.D., professor of ophthalmology and visual sciences and molecular and integrative physiology, recently had his National Institutes of
Health research grant (R01) renewed for his project,
Retinovascular Pathophysiology: Focus on Proliferative Retinopathy. Through his continued research,
Dr. Puro hopes to better understand the pathophysiological changes that accompany the abnormal growth
of retinal blood vessels, which is a serious complication
of diabetes and premature birth. He hopes this knowledge will lead to new therapies for these major sightthreatening disorders.
“This research is relevant because it may lead to
new pharmacological approaches for treating this
dreaded complication of diabetes,” says Dr. Puro.
“Despite the benefits of currently used therapies, the
complication of proliferative retinopathy continues to
be a leading cause of blindness. Findings of this research
could also extend to advances in the treatment of retinopathy of prematurity and other serious eye disorders
in which aberrantly growing blood vessels cause sightthreatening damage to the retina.”
Dr. Donald Puro with postdoctoral fellow Maho Shibata, M.D., Ph.D.
Researching Retinal Detachments
i n o u r p e d i at r i c pat i e n t s
Cagri G. Besirli, M.D., Ph.D.,
assistant professor and pediatric
retina specialist, received a National
Institutes of Health K08 grant for
his project, Neuroprotection in
Pediatric Retinal Detachment.
Pediatric retinal detachment
is a significant cause of childhood
blindness in developed countries. One of the common
characteristics of inherited or acquired pediatric retinal
detachments is leakage of fluids — including blood
and fat-like substances — under the retina that causes
photoreceptors to separate from the retinal pigment
epithelium (RPE) and eventually die.
However, once the retina is re-attached, many
children regain limited vision, which indicates that
some photoreceptors are able to survive separation
from the RPE. Dr. Besirli plans to use both animal
model and human samples to identify the protective
mechanisms on a cellular level that keep photoreceptors
alive. “The goal of the five-year study,” says Dr. Besirli,
“is to develop novel therapies to prevent vision loss in
our youngest patients with retinal disorders.”
15
Immunofluorescent stain of the anterior segment (front of the eye) in a mouse model, from the lab of Philip Gage, Ph.D.
Finding the Pathways to
Regenerative Medicine
What we can learn by studying
how the eye develops and how
it responds to injury
In the years ahead, regenerative medicine could spawn a
new class of therapeutics to treat eye disease and restore
vision. New cell-based therapies might promote healing
by inserting new cells into diseased tissue or reactivating
stem cells that proliferated during the eye’s development.
Scientists at the Kellogg Eye Center are pursuing
two broad avenues of research to realize the promise of
regenerative medicine. Some are studying the fundamentals of eye development to understand more completely
how the structures of the eye are formed and what happens when things go awry. Others are investigating mechanisms of tissue and cell regeneration in the mature eye.
In their experimental models, our scientists have
observed populations of stem cells that they believe
could be harnessed for therapeutic uses. Zebrafish, for
example, have the unique and fascinating capacity to
generate new cells in response to injuries to the retina
and to muscles of the eye.
16
Here are a few examples of how Kellogg scientists
are laying the groundwork to advance the field of
regenerative medicine:
How the drainage channel develops and how
errors can lead to glaucoma in children
Understanding how the eye develops is the starting
point for regenerative medicine. Brenda L. Bohnsack,
M.D., Ph.D., whose clinical specialty is pediatric glaucoma, studies how the front (or anterior) part of the eye
develops, using the zebrafish as her model. Missteps in
development in this area can result in eye diseases like
congenital glaucoma.
One of the unique aspects of eye development in
both zebrafish and humans is the role of the neural
crest, a population of stem cells that exist in the embryo
for a short time and then differentiate — or change —
into cells that form structures all through the body,
including the eye.
These neural crest cells give rise to a structure
central to Dr. Bohnsack’s research and clinical practice.
“I am interested in the angle at the junction of the iris
and cornea that allows fluid to drain from the eye,”
Brenda Bohnsack, M.D., Ph.D., (center) with Bahaar Chawla and Amy Stevenson.
Philip Gage, Ph.D., (far right) with Chen Kuang and Lisheng Chen, Ph.D.
she says. “When the drainage channel is not properly
formed in the embryo, the result can be elevated eye
pressure, damage to the optic nerve, and congenital
glaucoma.”
According to Dr. Bohnsack, “Once we understand
at the genetic level how the healthy eye develops, we
can study what goes wrong when disease occurs and
intervene either by rebuilding or repairing these essential channels.”
Dr. Bohnsack has been awarded a National
Institutes of Health K08 grant to study regulation
of the neural crest and its implications in congenital
eye disease.
mature eye. When it is withdrawn in experimental
models, the optic nerve deteriorates — and glaucoma
is induced.
The discovery is significant because it now appears
that Dr. Gage has an “inducible” glaucoma model that
allows scientists to observe how the disease develops
over a narrow timespan. “The rapid onset of optic
nerve change in our model, as compared to others,
makes this a useful resource for our lab and for the
larger glaucoma community,” says Dr. Gage. “The
model could also be used to test the effectiveness of
new therapies for preventing glaucoma and vision loss
often associated with the disease.”
Studying a gene that influences the development of structures in the front of the eye
Understanding eye muscle regeneration
and the path to new therapies
Building the fine structures of the front of the eye requires coordination and communication among embryonic cell tissues, a process that is “quite an engineering
feat,” says developmental geneticist Philip J. Gage, Ph.D.
The way his lab “listens in” on the process, says
Dr. Gage, is to study PITX2, a gene whose function
is to control the activity of other genes. Dr. Gage has
identified the gene as a key regulator at multiple stages
of eye development. A mutation in PITX2 is a cause of
Axenfeld-Rieger syndrome, a condition marked by abnormalities in the front of the eye. About half of those
with this syndrome will develop glaucoma, usually in
childhood or adolescence.
Dr. Gage has also shown that PITX2 is essential in
developing both the cornea, the clear front of the eye,
and the angle structure. And most recently he reported
that the gene is required to maintain the health of the
Alon Kahana, M.D., Ph.D., scientist and oculoplastics
surgeon, is interested in the orbit of the eye, the bony
structure that protects the eye, and the muscles that
control eye movement. When eye muscles do not develop properly, one result can be congenital strabismus,
a disorder in which the child’s eyes are not aligned,
resulting in compromised vision.
New therapies for strabismus and other eye muscle
disorders could emerge from Dr. Kahana’s unique
zebrafish model. In a recent study, he found that zebrafish can regenerate new eye muscle tissue even after
50 to 80 percent of the muscle has been removed.
Dr. Kahana has been awarded a National Institutes
of Health R01 grant to identify the biological mechanisms that underlie repair and regeneration of eye
muscle tissue in response to injury. “Understanding
more about this remarkable capacity for regenerating
17
Alon Kahana, M.D., Ph.D., left, with researchers Bahaar Chawla
and Philip Kish, Ph.D.
Peter Hitchcock, Ph.D., second from left, and his research team, Travis D’Cruz, Ph.D.,
Esther Gramage, Ph.D., Dilip Pawar, Ph.D., Caroline Walsh,
Laura Kakuk-Atkins, M.S., and Scott Taylor, Ph.D.
healthy tissue will certainly contribute to the broader
“We are interested in the early events that give rise
fields of stem-cell biology and regenerative medicine,”
to the mature retina: the proliferation of embryonic
says Dr. Kahana, the Helmut F. Stern Career Developcells and their differentiation into functional cell types,”
says Dr. Hitchcock, professor of ophthalmology and
ment Professor.
visual sciences and cell and developmental biology.
Studying the regenerative process is leading the
Dr. Hitchcock’s lab also investigates mechanisms in
Kahana lab to investigate changes in the brain that
the mature retina that govern stem-cell-based regeneraoccur when eye muscles are injured. “Because the brain
tion of photoreceptors after injury. “In a broad sense,”
controls neural activity related to vision, we are beginsays Dr. Hitchcock, “we hope to anning to ask how the brain remodels
and regenerates in response to injury
“Regenerative processes swer the question: ‘What does a stem
cell require to make a photoreceptor?’
to the eye muscle,” says Dr. Kahana.
are
tightly
controlled
—
And, we’re looking at this in a model
And, he adds, “the timing is
where regeneration occurs in a very
fortuitous.” The National Eye Instiexquisitely
controlled
—
robust way when photoreceptors are
tute has issued its key “audacious”
destroyed.”
research goals. Number one on that
and
it’s
this
exquisite
This vigorous action is not unlike
list involves remodeling neural connections in the visual system.
the proliferation of cells in cancer.
control that we have to
“One of the themes that is clear to
everybody working in these fields is
Investigating development of
understand.”
that developmental, regenerative, and
the retina and regeneration
cancer biology are mechanistically
after injury to the adult retina
— Peter F. Hitchcock, Ph.D.
linked,” says Dr. Hitchcock. “SignifiResearch in the lab of neurobiologist
cantly, however, cell proliferation in cancer is unreguPeter F. Hitchcock, Ph.D., spans the biological
lated, which is a hallmark of that disease. By contrast,
spectrum. Using the zebrafish model, his lab studies
regenerative processes are tightly controlled — exquithe molecular and cellular processes that govern both
sitely controlled — and it’s this exquisite control that we
the development and regeneration of retina cells.
have to understand.”
Among these cells are photoreceptors, light-sensing
The zebrafish’s capacity to repair tissue could be an
cells essential for vision that are part of the central
apt model for stem-cell-based therapies. “We hope some
nervous system. When these cells do not form properly
part of our work informs that approach to treating
or become damaged later in the adult eye, diseases
brain and retinal injuries,” says Dr. Hitchcock.
such as age-related macular degeneration and retinitis
pigmentosa can occur.
18
Is It Possible to
Reprogram Cells to
Repair Eye Tissue?
Epigenetics provides insight into how genes function and the mechanisms that control them — and
could pave the way for regenerative therapies
Through the study of epigenetics, Dr. Rajesh Rao sees potential for cell-based
therapies for eye disease.
cells contain the same DNA, their genes are expressed
One of the most fascinating therapies being discussed
differently, which creates distinct cell identities,” says Dr.
today is the possibility of reprogramming cells to repair
Rao. “Using small molecules that can manipulate chemidamaged tissue. Retina specialist Rajesh C. Rao, M.D.,
cal modifications in chromatin in the laboratory, a skin
points to several studies in which skin-derived cells have
cell could be reprogrammed to become a functioning
been coaxed to become brain and heart cells in a petri
retinal cell.”
dish. While it will be some years before the technology
Dr. Rao will study specific types of epigenetic
can be applied to treating disease, Dr. Rao is joining
regulators associated with gene expression and represU-M and Kellogg scientists in applying knowledge from
sion, but whose function is not yet
the field of epigenetics to advance
“Using
small
molecules
understood in the retina. “A better
regenerative therapies in the eye.
understanding of chromatin-mod
Epigenetics, meaning “after or bethat
can
manipulate
ifying enzymes may one day allow
yond genetics” refers to modifications
reprogramming of diseased or scar-asin genes that lead to variations in exchemical
modifications
sociated fibroblast cells (as in macular
pression of those genes. The modificadegeneration) into functional, light
tions, some of which are passed from
in chromatin in the labosensing cells,” says Dr. Rao.
one generation to the next, can be
Dr. Rao is collaborating with
induced by environmental factors such ratory, a skin cell could
researchers involved in epigenetics and
as diet and smoking that can activate
drug discovery across the University.
or silence genes.
be reprogrammed to
“We want to use stem-cell biology
“Gene expression is regulated by
and epigenetics as languages to better
chemical modifications to DNA and
become a retinal cell.”
understand disease mechanisms in
its associated proteins,” says Dr. Rao.
— Rajesh C. Rao, M.D.
blinding retinal diseases, with the goal
“DNA is wrapped around proteins
of developing novel pharmacologic
to form a structure called chromatin.
gene and cell-based therapies for our patients.”
Chromatin can be opened and closed. When chromatin
around specific genes is open or relaxed, gene expresDr. Rao has joined the Department under the National
sion can proceed. When chromatin is closed or tightly
Eye Institute (NEI) K12 Michigan Vision Clinicianwound, the gene cannot be expressed and is silenced.”
Scientist Development Program, an award that provides
Under a National Eye Institute K12 grant, Dr. Rao
training and mentorship to young ophthalmologists
will investigate the mechanisms that turn our genes “on”
planning to develop careers as clinician-scientists. The
and “off,” and, ultimately, either lead to a diseased state,
Department is one of only six in the nation to be able
or to health in the eye and retina. “Epigenetics explains
to offer this award.
why a skin cell is different from an eye cell. While both
19
Research by Kellogg Team Leads to
Largest Multi-Center Clinical Trial
for Graves’ Eye Disease
Findings provide inroads into novel therapies
with potential to safely minimize severity and
duration of disease
Individuals suffering from Graves’ eye disease (GED),
also known as thyroid eye disease (TED), have had
very few treatment options available to them — without
the risk of significant side effects and safety concerns.
Now a clinical trial evaluating the efficacy and safety
of a new therapy for TED has begun, the result of over
25 years of research led by the Kellogg team of Terry
J. Smith, M.D., an endocrinologist and Frederick G.L.
Huetwell Professor of Ophthalmology and Visual Sciences, and Raymond S. Douglas, M.D., Ph.D., a specialist in Graves’ eye disease and renowned oculoplastics
surgeon.
Dr. Terry Smith with patient Ruth Horyn and clinical research project manager Karen King.
20
TED is a visually debilitating and potentially disfiguring condition associated with Graves’ disease, an
autoimmune disorder that causes the overproduction of
thyroid hormones, or hyperthyroidism. Approximately
one million Americans have been diagnosed with
TED. Symptoms include swelling of the eyelids and
tissue around the eye, a constant stare, bulging eyes,
eyelid retraction, and loss of vision. In severe cases, the
cornea may ulcerate, or the optic nerve may be damaged. Either complication may result in permanent loss
of vision if not treated appropriately. Approximately 25
to 50 percent of individuals with Graves’ disease will
develop TED.
“The eyes are particularly susceptible to Graves’
disease because the autoimmune attack often targets
the eye muscles and connective tissue surrounding the
eye,” says Dr. Douglas. “This occurs as a consequence
Fluorescent imaging of Graves’ disease fibroblasts treated with insulin growth
factor-1 (IGF-1) with or without the steroid, dexamethasone (Dex).
Sonal Trivedi, clinical research coordinator; Dr. Raymond Douglas; Karen King, clinical research project manager; Dr. Terry Smith.
“The goal of this trial is to determine whether
of these tissues containing proteins that are shared with
administering RV 001 early in the active phase of TED
the thyroid gland.”
will safely minimize the severity and duration of the dis
The team’s findings point to the apparent involveease, have a favorable effect on long-term outcome, and
ment of the insulin-like growth factor 1 (IGF-1) receplessen the need for corrective surgeries,” says Dr. Smith.
tor in Graves’ disease and other autoimmune diseases.
“This investigative drug has worked in the test tube and
“Specifically, we have found that there is an unusually
now it could work in the human being.” Moreover, the
high presence of IGF-1 receptors on cells surrounding
team has emerging evidence that RV 001 might be at
the eye in TED,” says Dr. Smith, widely recognized
least as useful in treating rheumafor his groundbreaking research
“This
investigative
drug
toid arthritis and type 1 diabetes.
on treatments for TED and related
Sponsored by River Vision
autoimmune disorders.
has
worked
in
the
test
Development Corporation, the
Building on this discovery, an
clinical trial will enroll approxioutgrowth of basic science research
tube and now it could work
mately 84 individuals who have had
conducted at the University of Calisymptoms of TED for less than six
fornia, Los Angeles, and then at the
in the human being.”
months and who have not received
Kellogg Eye Center, Drs. Smith and
any treatment, with the exception
Douglas have initiated the largest
— Terry J. Smith, M.D.
of lubricating eye drops. Drs. Smith
multi-center clinical trial for TED in
and Douglas are the principal investigators of the study
the United States, called the Graves’ Eye Disease Study.
encompassing 22 study centers throughout the country
The study will examine the potential therapeutic
that will participate in the trial, which is expected to
benefit of a monoclonal antibody known as RV 001
run through 2014.
that blocks the IGF-1 receptor, originally developed as a
cancer drug. Although the drug failed to exhibit efficacy
To learn more about the trial visit:
in patients with cancer, the team believes it may be a
https://umclinicalstudies.org/HUM00073174
useful therapy in interrupting the TED disease process,
given its specific targeting of the IGF-1 receptor.
21
Inv es t i g at i n g s u b co n s c i o us
Dr. Kwoon Wong has been awarded new grants to study subconscious response to light.
Neuroscientist Kwoon Y. Wong, Ph.D., has been
awarded a National Institutes of Health R01 grant for
his project, Physiology of Intrinsically Photosensitive
Retinal Ganglion Cells.
Intrinsically photosensitive retinal ganglion cells
(ipRGCs) are recently discovered retinal nerve cells
that drive subconscious physiological responses to
light — such as regulating hormone secretion, enhancing
alertness, and synchronizing sleep timing to the light/
dark cycle. “Recent discoveries have shown that the
eye supports not only conscious vision but also various
subconscious physiological responses to light that are
crucial to our well-being,” says Dr. Wong. Under the
five-year study, Dr. Wong will investigate two aspects
of ipRGCs: the molecular mechanisms that enable
such cells to respond to light, and the communication
between these cells and other cells in the retina.
Dr. Wong has also received a Department of
Defense Army Research Office grant for another
22
project, Modeling Subconscious Vision, in which he
serves as a co-principal investigator. In this project,
Dr. Wong has teamed up with Daniel B. Forger, Ph.D.,
University of Michigan Department of Mathematics, to
construct mathematical models that explain the inner
workings of ipRGCs and related retinal cells. These
models will enable Drs. Wong and Forger to predict how
these cells would respond to any kind of light stimulus.
The long-term goal of these projects is to help develop light therapies for depression and sleep disorders,
novel lighting technologies that enhance productivity
at work and school, and better diagnostic tests for eye
disorders. In addition, these studies could lead to new
strategies for restoring vision in the blind. “Interestingly,
ipRGCs remain light-responsive in many people who
are blind,” says Dr. Wong. “A better understanding of
the physiology of ipRGCs should help us devise new
ways to enhance their photosensitivity, which could help
improve the visual capability of people who are blind.”
Kellogg residents gather in the state-of-the-art Kittendorf Resident Education Center.
Back: Neil Farbman, J.D., M.D., Lee Kiang, M.D., Ph.D., Abigail Fahim, M.D., Ph.D. Front: Maxwell Stem, M.D., Kevin Tozer, M.D., Denise Kim, M.D., Andrew Stacey, M.S., M.D.
Attorney’s Estate Gift
Creates a Legacy
Born in Detroit in 1937, Mr. Kittendorf moved with
his family to Sebewaing, Michigan, where he graduated from high school in 1955. He earned a bachelor’s
degree at Michigan State University and served for two
years in the U.S. Army. When he returned, he enrolled
of Learning and Hope
in the Detroit College of Law, joining the State Bar of
Roger W. Kittendorf, a Genesee County attorney and
Michigan’s Master Lawyers Section in June 1967.
businessman who passed away in late 2012, was a
He spent time as an assistant prosecutor for
thoughtful investor in organizations he believed would
Genesee County and as a lawyer for Vienna Township
make a difference in people’s lives. His generous supin Clio before opening a private office. He built a robust
port of the Kellogg Eye Center,
practice and invested in real estate
“As
a
student
and
an
adult,
which included gifts to research
throughout his career. In his free
and to a new resident education
time, he enjoyed golfing and internaI
have
always
admired
the
center, culminated with the news
tional travel. He continued working
that Kellogg would be the primary
until he passed away at the age of 75.
University
of
Michigan’s
beneficiary of his estate.
Mr. Kittendorf said he felt privi
As a long-time Kellogg patient
leged to be able to share his success
quest for excellence.”
and supporter, Mr. Kittendorf
with others, and while he requested
became a partner in the work
anonymity for the gifts he made
— Mr. Roger Kittendorf
that is done here. He engaged his
during his lifetime, the Kellogg Eye
physician, glaucoma specialist Sayoko E. Moroi, M.D,
Center is now able to thank him publicly, naming the
Ph.D., in conversations about research, which led to
Roger W. Kittendorf Resident Education Center.
his support of specific projects. As a former teacher, he
“Our patients have an incredible understanding of
was intrigued that Kellogg has one of the top programs
how precious eyesight can be — and how fragile,” says
in the country for training physicians who want to
Paul P. Lee, M.D., J.D., F. Bruce Fralick Professor and
specialize in ophthalmology. Mr. Kittendorf learned
Chair of the Department of Ophthalmology and Visual
that Kellogg hoped to build a state-of-the-art education
Sciences. “When they are able to help us help others,
center, and he made construction of the facility possible.
our impact is multiplied many times over. We are very
It opened on the sixth floor of the original Kellogg Eye
grateful for Mr. Kittendorf’s commitment to vision.”
Center tower in 2011.
“As a student and an adult, I have always admired
To support vision research, you can make the University
the University of Michigan’s quest for excellence,” Mr.
of Michigan a beneficiary of a 401K or other savings or
Kittendorf said at the time of his gift to the education
insurance plan. You can also designate funds through
center. “Since I have reached a point in life where I have
a will. For information, please contact Becky Spaly at
the resources to assist, I couldn’t resist the opportunity.”
734.763.0874 or at [email protected].
23
The Pipernos with the Symposium Organizing Committee. Back row: Paul Lichter, M.D., Bruno Piperno, Celeste Piperno, John Heckenlively, M.D.,
William Hauswirth, Ph.D., Alessandro Iannaccone, M.D., David Zacks, M.D., Ph.D.; Front row: Debra Thompson, Ph.D., Robin Ali, Ph.D.
Advancing a Shared Mission
A couple partners with Kellogg to host international conference on retinal diseases
When more than two dozen physicians and scientists
from around the world gathered in Tuscany this fall
to discuss innovative treatments for blinding retinal
dystrophies, hosts Celeste and Bruno Piperno realized
a long-held dream. They often help individuals with
eye conditions navigate the health care system in Rome,
where they own a business consulting firm and Mr.
Piperno seeks care for an inherited retinal condition.
Yet they have always wanted to do more. By partnering
with the Kellogg Eye Center and providing researchers
with the ideal location for an international scientific
meeting — Tenuta di Monaciano, a resort and vineyard
that has been in their family since the early 20th
century — they made a unique contribution to the field.
“This is a crucial time in retinal degeneration
research, and the need for us to work together as an
international community has never been greater,”
says meeting coordinator Debra A. Thompson, Ph.D.,
24
Professor of Ophthalmology and Visual Sciences and
Professor of Biological Chemistry at the University of
Michigan. “We are making great strides in gene and
stem-cell therapies, but pursuing key research imperatives could make us all more successful. Discussing
those potential next steps as a group was important and
very inspiring. The Pipernos made that possible.”
The Monaciano Symposium was designed to foster
collaboration and the development of shared policy
and research agendas. Participants defined five consensus goals needed to move the field forward in the next
decade and eight actions that could be undertaken collaboratively to achieve those goals. The group aims to
publish their findings in the coming year.
That outcome is exactly what the Pipernos had
in mind. Diagnosed with a retinal dystrophy many
years ago, Mr. Piperno has a deep appreciation for the
progress that is being made toward treatments and for
Researchers and physicians from seven countries participated in the Monaciano Symposium.
Tenuta di Monaciano (photos compliments of Richard Weleber, M.D., Casey Eye Institute)
the importance of global cooperation among scientists.
Director of the Retinal Degeneration and Ophthalmic
With strong ties to U-M — he earned a master’s degree
Genetics Service at the University of Tennessee Health
in business administration at U-M,
Science Center. Researchers
“This is a crucial time in retinal attended from eight states and
and his children have attended
seven countries.
programs at the Ross School of
degeneration research, and the
Business — he and his wife ap“In this age of digital connecproached Paul R. Lichter, M.D.,
tions, there remains no substitute
need for us to work together as for face-to-face interactions,”
with the idea for a conference.
The Pipernos provided lodgMr. Piperno says. “We hope the
an international community has
ing and meals for the Monaciano
Monaciano meeting will be reSymposium, while the agenda was
membered as a point for progress
never been greater.”
set by an organizing committee
in establishing the etiology and
that included Mr. Piperno’s
course of treatment for retinal
— Debra A. Thompson, Ph.D.
diseases, and we look forward
ophthalmologist, Alessandro
to the continuation and growth of the symposium’s
Iannaccone, M.D., M.S., who has a practice in Rome
international dialogue.”
and is Associate Professor of Ophthalmology and
Collaborating
with a leader in
gene therapy and cell transplantation
Robin Ali, BSc, PhD, FMedSci,
internationally known for his
research in gene and cell-based
therapy, will join the Department as
a Visiting Professor. Dr. Ali, professor of human molecular genetics,
directs the Department of Genetics
at University College London and
Moorfields Eye Hospital. While in
residence at Kellogg, Dr. Ali will collaborate with faculty
and trainees to advance research toward treatments for
inherited retinal disease.
As just one example of his groundbreaking research,
Dr. Ali led the team that carried out the first successful
transplant of light-sensitive photoreceptor cells taken
from a synthetic retina and grown “in a dish” from
embryonic stem cells. The study, published in the August
2013 issue of Nature Biotechnology, suggests that
embryonic stem cells could one day provide a potentially
unlimited supply of healthy photoreceptors for retinal
cell transplantations to treat blindness in humans.
In addition to collaborating with faculty on research
associated with retinal degenerations and inherited
ocular diseases, Dr. Ali will mentor new faculty, trainees,
and research staff in gene and cell therapy techniques.
He will work with our faculty to generate sponsored research grants, and to bring the most promising research
forward into clinical trials with the goal of developing
new therapies for patients with retinal disease.
Endowed Professorship
Honors Christine Nelson, M.D.
Award provides Dr. Nelson the opportunity
to advance her research in anophthalmia,
a congenital eye birth defect in which one
or both eyes do not develop
Department Chair Paul Lee, Dr. Christine Nelson, Mrs. Cheryl Frueh,
and Medical School Dean James Woolliscroft
the gene mutation and deficiencies in the mother’s diet
Oculoplastics surgeon Christine C. Nelson, M.D., has
during pregnancy may be responsible for the disorder.
been named the first Bartley R. Frueh, M.D. and Frueh
“When the mother and fetus carry the gene, we believe
Family Collegiate Professorship in Eye Plastics and
that treatment with vitamin A early in the pregnancy
Orbital Surgery. Dr. Nelson is Professor, Ophthalmolcould promote normal fetal ocular development,” says
ogy and Visual Sciences, and Professor, Department of
Dr. Nelson. “This is an exciting development with a
Surgery, Plastic Surgery Section.
relatively simple treatment that could have a global im
Dr. Frueh and his wife, Cheryl, established the
pact, improving the lives of individuals with a genetic
Lloyd and Virginia Frueh Research Professorship in
history of anophthalmia.”
Eye Plastics and Orbital Surgery in May 2007. This
Dr. Nelson also studies the related conditions of
title was later changed to include Dr. (Bartley) Frueh’s
microanophthalmia, in which one or both eyes are
name in 2010, after he unexpectedly passed away.
abnormally small, and coloboma,
Establishing a professorship
“Bartley
was
very
passionate
in which segments of tissue are
in his parents’ names meant
missing from various eye struca great deal to Dr. Frueh, as
about
research
in
the
field
of
tures. Moreover, she is known for
it created a lasting tribute to
her clinical expertise in the evaluthe values of education, hard
oculoplastics. He wanted to make
ation and treatment of adult and
work, and beneficence that
pediatric patients with tumors
they instilled in him.
sure that this arena remained
and other disorders of the eyelid
“Bartley was very passionand orbital disease.
ate about research in the field
vital and strong at Kellogg.”
“I am very humbled to be
of oculoplastics. He wanted
named the first Bartley R. Frueh,
to make sure that this arena
— Mrs. Cheryl Frueh
M.D. and Frueh Family Colleremained vital and strong at
giate Professorship in Eye Plastics and Orbital Surgery,
Kellogg,” says Mrs. Frueh. “Both he and Paul [Paul
an honor that will keep Dr. Frueh’s memory alive,”
Lichter, Immediate Past Chair of the Department]
says Dr. Nelson. “He was a great teacher and mentor
had a vision to see the Department evolve into a
to all of us at the Kellogg Eye Center. It was a privilege
world-class entity in oculoplastics. The beauty is
to know and work with him. His unmatched clinical
that Bartley was able to see this take place at Kellogg
and surgical skills, compassion, keen scientific intellect,
while he was still alive.”
and wonderful spirit will not be seen again soon.”
Under this professorship, Dr. Nelson will have
Dr. Nelson was also the first female recipient of
more resources to devote to teaching, mentorship, and
the prestigious Wendell Hughes Lectureship Award
her research in anophthalmia, a condition in which one
from the American Society of Ophthalmic and Plastic
or both eyes do not develop. Through her study of a
Reconstructive Surgery in 2012, and she joins a roster
seven-generation family, Dr. Nelson and her colleagues
of distinguished contributors to the advancement of
have identified a new gene for this eye birth defect.
ophthalmic plastic and reconstructive surgery.
Her research findings suggest that the combination of
26
With gratitude for gifts made from July 1, 2012, through June 30, 2013
Annual Honor Roll
of Donors
With heartfelt thanks to donors
Susan J. Lane
Richard and Jane Manoogian
THE RDH12 Fund for Sight
Timothy and Laurie G. Wadhams
Richard N. and Marilyn K. Witham
who made gifts from July 1, 2012,
$10,000 to $49,999
through June 30, 2013. Included in
American Diabetes Association, Inc.
Bell Charitable Foundation
Edward P. and Kathryn M. Bellas Trust
Mary L. Boyers Trust
Sandra and David Detrisac
Ann A. Edwards
Jacqueline A. Forrest
Cheryl Terpening Frueh
M. and H. Ghandour
Al and Colette Kessel
Drs. Vikas and Bithika Kheterpal
Paul and Jennifer Lee
William C. and Sally A. Martin
The Meijer Foundation
Larry G. Miller
Bruce and Roberta Oliver
Michael Pachtman
James and Nancy Ravin
Shirley M. Schaible Estate
Mickey and Karen Shapiro
Elmer and Sylvia Sramek
Charitable Foundation
Mildred E. Swanson Foundation
Margaret F. Vezina Estate
The Honorable Nancy C. Wheeler
this listing are contributors whose
donations are part of multi-year
pledges.
$1,000,000 and above
W.K. Kellogg Foundation
$500,000 to $999,999
Edwin E. Meader Estate
$100,000 to $499,999
The Foundation Fighting Blindness
Jerome Jacobson Foundation
Juvenile Diabetes Research Foundation
Roger W. Kittendorf, TTEE
Philip J. Lo Presti Estate
Research to Prevent Blindness
Winifred A. Stedman Trust
The Harry A. and Margaret D.
Towsley Foundation
$50,000 to $99,999
Anonymous Donor (1)
Thomas W. Breakey
Frances and David H. Grossman
W.R. Kenley Estate
$5,000 to $9,999
Michael and Joanne Bisson
Cynthia L. and Jason M. Burgett, M.D.
Don and Betts Chisholm
Scott M. Corin and Nina Blumenthal
Jane and Irwin Deister, Jr.
Joe and Beth Fitzsimmons
Richard and Lisa Garfinkel
Tarek S. Hassan and
Diana M. Gomez Hassan
Helen and Richard Kerr
Carolyn R. and Paul R. Lichter
Corey A. and Nancy J. Miller
Gerald and Joyce Trocchio
Danny D. Wang and Yili Wang
W. Scott and Jill Wilkinson
$1,000 to $4,999
Gerald and Gloria Abrams
Anthony and Mary Adamis
Amjad Z. Ahmad, M.D.
Anonymous Donors (2)
Steven and Carol Archer
Betty Baier and Mark Kesson
Harry and Patricia Bash
Anne and Terry J. Bergstrom
Lana L. Berry
Eleanor E. Brownell
Michael J. Bueche, M.D.
Bruce D. Cameron, M.D.
Margaret Campbell
Keith D. and Cheryl Carter
Mark and Janet Cichowski
Mark and Judith Cohen
Claude M. Coleman
Mr. Frank and Dr. Theresa Cooney
Ruth E. Cressman
Monte A. and Kristen G. Del Monte
Rosemarie DeLand
“Contributions from Annual Fund donors will
help us maintain our state-of-the-art confocal
and multi-photon microscopes. Nearly every
scientist at Kellogg uses these high-resolution
instruments to obtain precisely detailed images
of cells and tissue that are needed to advance
our research on eye disease and treatment.”
— David A. Antonetti, Ph.D.
Professor
27
“We are extremely grateful for donor
support that has enabled us to develop
“RetDegenDx,” a computer model to
help us identify more precisely the
causative mutations for patients with
inherited retinal degenerations. By
providing our patients with a genetic
diagnosis, we can offer genetic counseling on the probable course of their
disease and the likelihood that their
siblings or children may be affected.
And as gene therapies are developed,
we can alert patients to clinical trials
with treatments that target their
specific mutation.”
— Thiran Jayasundera, M.D.
Assistant Professor
28
J. McGregor and Christine Dodds
Raymond and Jodi Douglas
Michael and Elizabeth Eichler
Hal and Donna Estry
Gary and Kay Feaster
Triford Foundation
Margaret E. Gallup
Janice Gault and
James F. Vander, M.D.
Larry and Mary Gerbens
Mr. and Mrs. Waleed K. Gosaynie
Joanne R. Gradowski
Daniel and Norma Green
Richard F. and Susan Gutow
Kenneth Haller
Theodore and Naomi Harrison
David S. Hemmings, M.D.
Myron Hepner
Barry and Mary Ann Hoffman
Robert O. and Carolyn S. Hoffman
James and Kathy Holmes
Walter L. and Barbara J. Hungerford
Denise A. M. John, M.D.
A. Timothy Johnson, M.D., Ph.D.
James A. Johnson
Professor Judy M. Judd
Daniel and Rose Kachnowski
Nancy and Jeffrey Kahn, M.D.
Ann Novak-Krajcik and
Joseph Krajcik, M.D.
Kim Lindenmuth and Matthew Bueche
William W. Love
James Albert Maraldo
Dr. and Mrs. P. Anthony Meza
Joel and Susan Mindel
Dean and Lynn Mitchell
Ken and Pat Musson
John P. and Ginger G. Myers
Dr. Michel and Alice Nasif
Pam W. Parrish
Allen and Kathy Pearce
Michael Petersen and
Elizabeth Binasio
Mark and Kimberly Phelan
Jeffrey A. Pike
Scott M. Pinter, M.D.
Playoffs Sports Bar
Donald and Debra Puro
Dr. and Mrs. Alfred G. Shrosbree
Dr. and Mrs. Gregory L. Skuta
H. Kaz Soong and
Barbara A. Nevins-Soong
Peter K. and Faye B. Speert
Mike Stolnack and Tina D. Turner
Alan and Gail Sugar
Bernard E. Sullivan
James B. Thompson and
Mary Ann Brandt
Triford Foundation
Richard L. and Kay E. Watnick
Lee S. and Stephen T. Webster
John and Carol Weigel
George C. and Cindy Whitaker
Marina V.N. and Robert F. Whitman
Alfred and Carol Wick
XI Chapter of Delta Gamma
Foundation
$500 to $999
Roger D. Arnett
Everton and Saundrett Arrindell
Mrs. Jennie Biggs
Duane and Jean Bingel
Henry A. Boldt Trust
James and Jacqueline Bowen
Richard and Enid Carlin
Anne M. Chase
Michele Tameris Cook
D & M Lumber Products Company, Inc.
Roland and Louise W. DeMartin
Roberta DeMott-Friberg
Gayle D. Dickerson
Dr. M. Kenneth and Arvene Dickstein
Deborah Eadie
Dr. John Fennig and
Dr. Martha M. Wright
Michael Fetters and Sayoko Moroi
Dennis and Christine Fornal
William F. Frederick
Gianfranco Gabbianelli
Harry C. Gibson, M.D.
Kathryn G. Gray
Geza L. and Elizabeth F. Gyorey
Jane Hakken
David J. Harris
Mark and Mary Hetrick
Millicent Higgins, M.D.
Charles A. Hutton
David A. and Patricia D. Johnson
Michael A. and Kim M. Kipp
James G. and Carolyn Knaggs
Frank J. Konkel
Professor Emeritus Myra A. Larson
Richard Alan Lewis and
Patricia N. Lewis
Nancy E. and
James E. MacVicar, M.D.
Judge Joe B. McDade and
Mrs. Mary W. McDade
Mary L. Meyer
Betsy and Ken Nisbet
Pizza House Ann Arbor
Hans H. and Virginia A. Rae
Iva Jean Roe
David A. Rogers
Jonathan and Robin Rowe
Drs. Michael and Mary Ruddat
Perry and Faith Schechtman
Donald and Jane Schriver
Ted and Mary Ann Simon
Alma W. Smith
James P. and Dorothy Symons
Frank D. Tennent
Thomas G. Varbedian, M.D.
Drs. Adrienne West and
Mark Hemmila
Jung and Chiung Yao Wu
$100 to $499
Ann T. Alexander
Kevin Alfonso
Adeela Alizai and Asad Ansari
Colonel and Mrs. Richard W.
Anderschat
Dr. Krista Anderson
Jack and Mary Badalamenti
Beverly and George Baker
Lawrence A. Barnes
Anne and Donald F. Baty, Jr.
Stanley and Joy Berent
Lois Bereza
Dr. and Mrs. Werner G. Bergen
Rhoda L. and Roger M. Berkowitz
William and Patricia Berlin
Cagri and Sheila Besirli
Garry N. Binegar, M.D.
Michael and Clarita Bishel
Jonathan and Jill Bixler
Gerald R. and Ann L. Black
Donald and Georgia Boerma
Myrtle B. Bonem
Stephen and Danielle Boorstein
Frances R. Bosel
Daniel L. Braden
William and Julie Bromley
Gene Brown and Dee Oliverio
Henry J. and Jean L. Brown
Margaret Brown
Arsenia Bumgardner
Frederick G. and Marion F. Burgett
Gregory L. and Marlene M. Burhans
Wilbur and Carolyn Burkett
Michael A. and Diana L. Burnstine
Donald V. Calamia
Norman and Maureen Campbell
Arlene R. Caon
James and Jennifer Carr
J. R. and Elaine J. Carson
Claudette J. Casello
Dr. L. Ross Chambers
Robert and Kay B. Chesebro
Hideki and Tomomi Chuman
Antonio and Elizabeth Ciciretto
Marilyn Citron
R. Kent Clark
Martha and James Cleary
Ms. Alice S. Cohen
Dr. Clare R. Coles
Carl and Maria Constant
Frank L. Cooper
Patrick and Laura Coppens
Ellen L. Coulthard
Kim and Loraine J. Cranor
MargaretAnn Cross and
James Van Fleteren
Roland and Susan Cull
James and Marylyn Cumming
William and Carol Cutler
John and Elizabeth Dallas
Dolores D. Daudt
James E. Davies
Prof. William and Virginia Dawson
Joseph and Theresa DeMaria
James R. Devine
David J. Disser
John A. Dodds
Donald A. Dodick
Mr. and Mrs. Kenneth R. Dornbrook
Deborah Drous
Jeanette R. Duckworth
Mr. and Mrs. Wilbert L. Ehmann
Jonathan Eisengart and Jodie Rich
George Evans
Blanche J. Felice
Bryn A. and Suzanne M. Fick
Bruce and Susan Furr
Charles A. Gallup
Michael J. Geiss, III, and Tina Taggart
Jane and Robert Gelman
Richard and Jacqueline Gilbert
Lisa R. Gould
Richard L. Greer
Norman Grigsby
Steven and Iris Haak
Margaret Hagen
Charlotte Hanson
Noriko and Dr. Ken Hashimoto
Gerald and Mignon Heppler
Ruth Heyn, M.D.
Conrad and Jeanne Heyner
Dr. Frederick J. Heyner
Tom S. Hill
Peter J. Hirth
Richard and Jane Hiss
Timothy Hogan and Lindsey Wills
Margaret M. and James E. Hughes
Hull Brother’s Rental, Inc.
Illinois Tool Works Foundation
Richard and Anne Jackson
Elizabeth L. Jacobs
Mr. and Mrs. Kenneth B. Johnson
Mark and Linda Johnson
Reid and Donna Johnson
Artie M. Jones
Baerbel Juenger
George H. and Jo A. Jury
Ruth L. Kalin
Ariane Kaplan and Adam Stein
“Due to the generous support of the
W.K. Kellogg Foundation, we have the
potential to decrease disparities in
children's eye care across Michigan.
The active collaborations we now have
with the childhood vision screening
programs conducted by the State
of Michigan and the Lions Clubs of
Michigan simply would not have
happened without the Foundation’s
pivotal and generous support. This
serves to emphasize the impact of
private donor support.”
— David C. Musch, Ph.D., M.P.H
Professor
29
Jill Taft Kaufman
Robert B. Kaufman, M.D.
Rosemary S. Kaye
Marianne and Mike Kessel
Ralph and Priscilla Kinney
Shirley D. Kline
Donald L. Klopcic, Sr.
Alexandra Klos
Thomas C. and Mary J. Knight
Theodore and Caroline Korn
Drs. Teresa and Norman Krieger
Susan and James Krucki
Gerald and Dorothy Kurtz
Marie Lane
Louis and Gail LaRiche
Kurt K. Lark, M.D., and
Rebecca L. Lark, M.D.
Dave H. and Peggy Lee
Lucille Lefler
Robert C. Leland, Jr.
Gary Lelli and Kelly Bottger
J. Paul and Cheryl L. Lemieux
Jeanne M. Lerchen
Danute M. Leveckis, M.D., and
Timothy Van Every, M.D.
Barbara R. Levine
Giant C. Lin and Linda Zhang
Sherry L. Lindahl
Mark and Carol Loessel
Uday Loka
Thomas Longworth and Carol Cramer
Joan Lowenstein and Jonathan Trobe
Lonnie L. Loy
Fred A. Lustig
Michael and Donna Maddin
Joseph L. Maggini
Leo and Kathryn Maguire
Richard and Barbara Mannis
Marvin and Shirley Markgraff
Eugene and Sandra Matsco
Regent Olivia P. Maynard and
S. Olof Karlstrom
Robert J. and Marilynn McDonald
Professor and Mrs. Wilbert J.
McKeachie
Lloyd and Helen McKee
Donald and Diane Meitz
Mr. Somsak Metriyakool
Herbert R. and Carolyn M. Metzger
Laurie and Frederick Metzger
Shahzad I. Mian and Uzma Ahmad
William and Caroline Michaluk
Steven J. Miller
Helen L. Mitchell
Ms. Marlene M. Moleski
Peter Montana
John and Linda Morrison
Richard G. Mosteller
Padmaja R. and Konda B. Mouli, M.D.
William J. Mundus
Alphonsus C. Murphy
Stanley Nalepka
Christine C. Nelson and
Willis C. Lillard
Catherine E. Nesbitt
Gordon and Vernie Nethercut
Harry and Leeta Nistel
Paul Olson and
MaryClare Denk Olson
Mohammad and Elizabeth Othman
Kazuo Otomo
Mark E. and Barbara C. Overland
Kishan Padakannaya
Edmund and Elaine Palmer
John and Sophie Papajohn
Joseph and Betty Pavka
Keith and Janet Lee Perkins
Donald and Dorothy Peterson
Pfizer Foundation
James and Nancy Pflasterer
“Generous support from a donor has aided my research
on rare, life-threatening eye cancers that might not
otherwise receive sufficient public or federal grant support.
With research findings to help us better understand and
manage these eye cancers, we have the opportunity to
improve patient outcomes.”
— Hakan Demirci, M.D.
Associate Professor
30
Luke R. and Joy M. Pinkerton
Sheryl and Douglas Podlewski
Larry and Maureen Potocki
Rebecca and Eric Priebe
Drs. Douglas and Leslie Quint
Dr. Reza Rahmani and
Mrs. Ellen F. Rahmani
Anne and Robert Rapp
Stephen and Penny Reck
Mr. and Mrs. Walter F. Redmond
Ann M. Reed
William and Charlotte Rees
Fred and Sharon Regula
Christopher D. Reid
Robert O. and Alice M. Reisig
Charles S. Remenar
Julie Reno
Rita and Robert Reske
Ms. Ann M. Rice
G. Richard Rice
Jean Richardson
Amelie Riendl
Barbara and Art Rocco
Richard Z. and Edie W. Rosenfeld
Rennie and Michael Roth
Vicki L. Rothhaar
Robert M. and Judith S. Rubin
Robert T. and Marietta C. Samaras
Michael and Jeanette Santalucia
Drs. Edward M. and
Virginia M. Sayles
Donald R. and Barbara Scavarda
Linda and Thomas Schalek
Charles Schmitter and Allyn Ravitz
Willard and Judith Schneider
Eileen Schott
John and Karen Schultz
Marc Alan Schwartz
Dr. Drusilla L. Scott
Garrett R. and Emily K. Scott
David and Elvera Shappirio
Charles Sherman
Shore to Shore Community
Federal Credit Union
Kathleen A. Silverman
Simons Foundation
Kenneth S. Smith and Donna Geneseo
Rosemary W. Smith
Sue-Ellen Smith
Becky and Doug Spaly
John and Alexandra Starr
Virginia E. Stein
Peter and Louisa Stoll
Dale D. Stordahl
Thomas and Jane Stratford
Joel Sugar and Anita Gerber
Alan and Lori Summer
Wesley Szpunar
Edward and Karen Tenner
Christopher J. Thomas
Edward Thornhil
H. James Thrall
A. Richard Tischler
Prof. Nelly S. Ullman
Ray and E. Jean Valley
Yea-Yuan B. Van Egeren
Ronald Vanderlugt
Frank and Thelma Veres
Sue Vitous
Richard and Edith Wacksman
Arthur and Shirley Wade
Claudia M. Wagner
David R. Wagner
Thomas Walker
Ora Pescovitz, M.D., Executive Vice President for Medical Affairs
William K. Wallach
Christian and Ella Weber
Maureen Wegryn
Cyrus R. and Susan C. Wellman
Dr. and Mrs. William W. Wells
James H. and Mary Anne Winter
Jeneane Wise
George E. Wittbrodt
Rolf K. and Helen L. Wohnus
Maria A. Woodward and
Jeremy Wolfe
Richard L. Wresche
Ford L. Wright
Michael B. and Kathleen M. Yang
Prof. Emer. York-Peng E. Yao and
Mrs. Cynthia C. Yao
Jean Birkhill, Dr. Raymond Douglas, and Fred Birkhill
Victors for Michigan, Victors for Vision
Friends and supporters of the W.K. Kellogg Eye Center
gathered to learn more about Victors for Michigan,
the largest fundraising effort in University of Michigan
history. The Kellogg Eye Center will play a key role
in the U-M Health System’s campaign, which will be
formally rolled out in April.
Dr. Paul Lee with Lisa Mower-Gandelot and Jon Gandelot
31
In Memory Of
The Kellogg Eye Center is honored
to have received gifts in memory
of the following individuals:
Mathew Alpern, Ph.D.
Margaret J. Baier and John A. Baier
Dr. Clifford J. Bedore
Norbert Bereza
Ruth F. Clarke
Paul and Kate Coleman
Robert F. Connally
LeRoy Constant
Birdie E. Cooper
Dr. Ray Croasdale
Mary P. DeLuca
Patrick Dionise
Harold F. Falls, M.D.
Mr. Fleming
Richard Foster
F. Bruce Fralick, M.D.
Bartley R. Frueh, M.D.
Dana Shresta and Mrs. Gerulski
Martin J. Glenday
Robert I. Goldsmith, M.D.
Henry E. Gray
Dr. Hanan C. Heller
David Herald
Dr. Frank D. Johnson
Dr. Abdul Samad Khan
Adabelle R. Knief
Gloria Koenig
Dr. Myron Levine
Susan Lichter
Dad and Aunt Lu
Mr. & Mrs. Louis E. Maggini
Reba Marie McCann
Dr. Agnes C. McMenemy
Lamoine B. Metty
Barb Meyer
Charles Mule
Corrine M. (Simpson) Olson
Mary Lee Olson
Richard Priebe
Donald Prover
Ruth K. Robins
Carl D. Roe
William C. Rogers
Billie G. Rouches
Valeri Samaras
Julianna Simon
Dr. Newel Smith
Marvin Sorrell
Lillian E. Taylor
Florence M. Timmons
Marilynn Varbedian
Mr. George Vartanian
Jeffrey B. Wehking
32
Vera Weinberg
Elizabeth Wolner
Dr. George J. Zissis
In Honor Of
The following individuals were
honored through gifts to the
Kellogg Eye Center:
James L. Adams, M.D.
Terry J. Bergstrom, M.D.,
Professor Emeritus
Jill E. Bixler, M.D.
Michael Cumming
Susy Dallas
Hakan Demirci, M.D.
Karen Gould and Gary Saretsky
John R. Heckenlively, M.D.
Miss Ida Lucy Iacobucci
Inez and James
Mark W. Johnson, M.D.
Paul R. Lichter, M.D.
Roger F. Meyer, M.D.
Mark Milazzo
Sayoko E. Moroi, M.D., Ph.D.
Emma O’Farrell
Jill Oversier
Penporn Reck, M.D.
Sandi Santoro
Stephen J. Saxe, M.D.
H. Kaz Soong, M.D.
Carol L. Standardi, R.N.
Alan Sugar, M.D.
Clare Van Fleteren
Rebecca A. Wu, M.D.
David N. Zacks, M.D., Ph.D.
Bequests and Other
Planned Gifts
It is with deep gratitude that we
recognize the following individuals
for making the Kellogg Eye Center
a part of their estate plans:
Frank J. and Helga Arnold
Nancy Bender
Anne S. Benninghoff
Edward Berger
Rhoda L. and Roger M. Berkowitz
Robert D. Biggs, M.D.
Dr. Robert W. Browne
Mrs. Andrea Clark
Gloria P. and William E. Dean, Jr.
Jacqueline A. Forrest
Ralph M. Fox
Helen A. (Poorbaugh) Freedman
Larry and Mary Gerbens
Conrad L. Giles
Ed and Sue Gorney
Ida Lucy Iacobucci
Mrs. Harry Krashen
Edward and Duffy Ladenberger
Harry and Eva McGee
Marvin Joseph and Beverly McKenney
Bruce L. and Roberta Oliver
Alvin Perkiss
Sally J. Pryce
Joanne A. Rackham
Katherine M. Rackham
Alice and Ronald Shankland
E.H. Newel and Rosemary Smith
Russell A. Stephens and
Phyllis A. Capogna
June Stover
James B. Thompson and
Mary Ann Brandt
David and Jayne VerLee
Only those who gave their
permission are included above.
The Kellogg Eye Center greatly
values our donors, and we make
every effort to ensure the accuracy
of the honor roll. Please call us at
734.763.0875 if you note any errors.
Faculty honors and recognition
July 1, 2012 — June 30, 2013
Steven F. Abcouwer, Ph.D.
Editorial Board, American Journal of Physiology:
Endocrinology & Metabolism
Editorial Board, Journal of Clinical & Experimental Ophthalmology
David A. Antonetti, Ph.D.
Editorial Board, Tissue Barriers
National Eye Institute Study Section, Diseases & Pathophysiology of the Visual System
Jules and Doris Stein Professorship, Research to Prevent Blindness
Steven M. Archer, M.D.
Best Doctors in America
American Association for Pediatric Ophthalmology and Strabismus
Lifetime Achievement Award
Arthur Stickle Lecturer in Pediatric Ophthalmology,
Washington University Medical Center, St. Louis, MO
Brenda L. Bohnsack, M.D., Ph.D.
Career Development Award, Research to Prevent Blindness
Grant M. Comer, M.D., M.S.
Theresa M. Cooney, M.D.
Delegate, Michigan State Medical Society Board, Michigan
Society of Eye Physicians and Surgeons
Wayne T. Cornblath, M.D.
Education Liaison Committee, American Academy of
Ophthalmology
Monte A. Del Monte, M.D.
Castle Connolly Top Doctors
Member and Grant Reviewer, Scientific Advisory Committee,
Knight’s Templar Eye Research Foundation, Schaumburg, IL
Member, Editorial Committee for Pediatric Ophthalmology,
Eye Wiki, American Academy of Ophthalmology
Immediate Past Chair and Consultant, International Affairs
Committee, Association for Pediatric Ophthalmology
and Strabismus
Chair of the Program Committee, American Orthoptic Council
Hakan Demirci, M.D.
Raymond S. Douglas, M.D., Ph.D.
Top Doctor, U.S. News & World Report
The Orbit Society
American Academy of Ophthalmology Achievement Award
Susan G. Elner, M.D.
Victor M. Elner, M.D., Ph.D.
Top Doctor, U.S. News & World Report
Keynote Speaker: 13th International Congress of
Ophthalmology and Optometry China, Shanghai, China
Jerome I. Finkelstein, M.D., FACS
Patrice E. Fort, Ph.D.
Academic Advisor, Ophthalmology Research:
An International Journal
Editorial Board, Journal of Clinical & Experimental Ophthalmology
Bruce A. Furr, C.O., Ph.D.
Editorial Board, American Orthoptic Journal
Executive Committee and Board of Directors, American
Association of Certified Orthoptists
Christopher Gappy, M.D.
Bylaws and Rules Committee, American Association for Pediatric
Ophthalmology and Strabismus
Thomas W. Gardner, M.D., M.S.
Associate Editor, Diabetes
Director, Michigan Vision Clinician-Scientist Development Program
Reviewer, Diabetes Complications Consortium, National Institutes of Health
J. Donald Gass Award and Lecture, Ophthalmic
Photographer Society
Associate Editor, EYE, Journal of the Royal College of
Ophthalmologists, U.K.
Peter F. Hitchcock, Ph.D.
Editorial Board, Academic Editor, PLoS ONE
K. Thiran Jayasundera, M.D., FACS, FRCSC, FRANZCO
Associate Editor, BMC Ophthalmology
Denise A. John, M.D., FRCSC
Representative, Association of American Medical Colleges
Minority Faculty Career Development Seminar
33
July 1, 2012 — June 30, 2013
64th Proctor Lecture, University of California San Francisco,
San Francisco, CA
Gass Fluorescein Club
Keynote Speaker, North Coast Retina Symposium,
Cole Eye Institute, Cleveland, OH
Chair, Committee on Programs, American Ophthalmological
Society
Treasurer and Executive Committee, The Retina Society
Editorial Board, American Journal of Ophthalmology
Editorial Board, Retina
Editorial Board, Retinal Physician
Alon Kahana, M.D., Ph.D.
Editorial Board Member, Ocular Surgery News
American Academy of Ophthalmology, Editorial Committee for
the Basic and Clinical Science Course, Section 2 Book Revision
John Aure Buesseler, M.D., Visiting Professorship,
Mason Eye Institute, University of Missouri
Joseph Bowlds Lecture, Lahey Hospital and Medical Center,
Burlington, MA
Focus on Eye Health National Summit, Prevent Blindness America
Doheny Society of Scholars Award
Board of Directors, American Board of Ophthalmology
Board of Governors, Association for Research in Vision
Ophthalmology Foundation
Board of Directors, Doheny Eye Institute
Editorial Board, JAMA Ophthalmology
Advisory Board, American Academy of Ophthalmology,
Hoskins Center for Patient Safety and Quality
Paul R. Lichter, M.D., FACS
Board of Trustees, International Council of Ophthalmology
President, Academia Ophthalmologica Internationalis
Associate Editor, American Journal of Ophthalmology
Board of Directors, Foundation of the International Council
of Ophthalmology
Michael J. Lipson, O.D., FAAO
Advisory Board Member, Rigid Gas Permeable Lens Institute
34
Shahzad I. Mian, M.D.
Program Director’s Council, Association of University Professors
in Ophthalmology
Board of Directors, Cornea Society
American Academy of Ophthalmology, Councilor,
Cornea Program Committee
Ophthalmology Leadership Advocacy Group
Medical Director, Michigan-Eye Bank
Editorial Board, Cornea Journal
Policy and Position Review Committee Chair, Accreditation Board, Eyebank Association of America
Ralph & Sophie Heintz Lecture, The 38th Annual H. Bruce Ostler
Association of Proctor Fellows Meeting and Graduation
Albert D. Frost Memorial Lecture, The 56th Annual Postgraduate
Symposium in Ophthalmology, Columbus, Ohio
Best Paper of Glaucoma Session, American Society of Cataract
and Refractive Surgery, San Francisco, CA
Glaucoma Subcommittee, National Eye Health Education Program
Planning Committee, National Institutes of Health, Bethesda, MD
Ad Hoc Member, Diseases and Pathophysiology of the Visual
System Study Section, National Eye Institute
Ad Hoc Member, Bioengineering of Neuroscience, Vision and
Low Vision Technologies Study Section, National Eye Institute
Member, American Academy of Ophthalmology, Glaucoma
Preferred Practice Pattern Committee
David C. Musch, Ph.D., M.P.H.
Secretariat Award, American Academy of Ophthalmology
Member, Preferred Practice Patterns Committee, American
Academy of Ophthalmology
Member, Ophthalmic Technology Assessment Committee,
American Academy of Ophthalmology
Study Section (clinical trials special emphasis panel), National
Institutes of Health/National Eye Institute
Grant reviewer, Health and Medical Research Fund,
Government of Hong Kong
Editorial Board, Ophthalmology
Editorial Board, Retina
Christine C. Nelson, M.D., FACS
Beard Award Lecturer, American Society of Ophthalmic Plastic and
Reconstructive Surgery
Wendell Hughes Lecturer Award, American Society of Ophthalmic
Plastic and Reconstructive Surgery
Media Advisory Task Force, American Academy of
Ophthalmology
Basic and Clinical Science Course, Book 7, American Academy
of Ophthalmology Committee
July 1, 2012 — June 30, 2013
Donald G. Puro, M.D., Ph.D.
Julia E. Richards, Ph.D.
Winner, National Eye Institute Audacious Goals Challenge.
Proposal: Fountains of Youth for the Eye
Editorial Board, G3: Genes/Genomics/Genetics
Member, National Eye Institute-funded Glaucoma Human
Collaboration Consortium
Member, African-American Study Group Consortium
Member, Scientific Advisory Board, The Glaucoma Foundation,
New York, NY
Roni M. Shtein, M.D., M.S.
Resident Retreat Faculty Mentor, Heed Ophthalmic Foundation
Terry J. Smith, M.D.
Board of Scientific Advisors, Guthy-Jackson Foundation
Board of Directors, National Graves’ Disease Foundation
Chief Medical and Scientific Officer, National Graves’ Disease
Foundation
Michael W. Smith-Wheelock, M.D.
H. Kaz Soong, M.D.
Assistant Editor, Cornea
American Academy of Ophthalmology Lifetime
Achievement Award
Medical Director, Michigan Eye Bank
Keynote Speaker, Taiwan Ophthalmological Society
Joshua D. Stein, M.D., M.S.
American Ophthalmological Society
American Glaucoma Society Health Care Policy and
Reimbursement Policy Subcommittee
Member-at-Large, American Glaucoma Society Board of Directors
Research Committee, American Glaucoma Society
Membership Committee, American Glaucoma Society
Committee Member, American Academy of Ophthalmology,
Glaucoma Preferred Practice Patterns
Research to Prevent Blindness Physician-Scientist Award
Alan Sugar, M.D.
Editor-in-Chief, Cornea, Journal of the Cornea Society
National Institutes of Health Study Section, Ad Hoc,
Bioengineering of Neuroscience, Vision and Low Vision
Technology
Editorial Board, Ophthalmology
Medical Director, Michigan Eye Bank
Eye Bank Association of America Research Committee,
Paton Award Committee
Debra A. Thompson, Ph.D.
Executive Editor, Experimental Eye Research
Fellow, Association for Research in Vision and Ophthalmology
Susan S. Thoms, M.D.
Jonathan D. Trobe, M.D.
Joshua P. Vrabec, M.D.
Jennifer S. Weizer, M.D.
Member, American Academy of Ophthalmology Cataract
Registry Workgroup, San Francisco, CA
Member, American Academy Ophthalmology Committee
on Resident Education, San Francisco, CA
Maria A. Woodward, M.D.
Basic and Clinical Science Course Committee,
Member, Retina/Vitreous Knowledge Base Panel,
*Listings are limited to national and international awards,
named lectures, and roles in professional societies or
editorial boards. Only national peer-selected “Best Doctors”
and “Top Doctors” rankings are noted
35
Faculty publications
July 1, 2012 — June 30, 2013
Abcouwer SF, Antonetti DA. A role
for systemic inflammation in diabetic
retinopathy. Invest Ophthalmol Vis Sci.
2013 Mar;54(3):2384.
Abcouwer SF. Direct effects of PPARα
agonists on retinal inflammation and
angiogenesis may explain how
fenofibrate lowers risk of severe
proliferative diabetic retinopathy.
Diabetes. 2013 Jan;62(1):36-8.
Al Alam D, Sala FG, Baptista S, Galzote
R, Danopoulos S, Tiozzo C, Gage P,
Grikscheit T, Warburton D, Frey MR,
Bellusci S. FGF9-Pitx2-FGF10 signaling
controls cecal formation in mice. Dev Biol.
2012 Sep;369(2):340-8.
Albertus DL, Schachar IH, Zahid S,
Elner VM, Demirci H, Jayasundera KT.
Autofluorescence quantification of benign
and malignant choroidal nevomelanocytic
tumors. JAMA Ophthalmol. 2013
Jun 20:1-5.
Allexan SS, Byington CL, Finkelstein JI,
Tarini BA. Blindness in Walnut Grove:
How did Mary Ingalls lose her sight?
Pediatrics. 2013 Mar;131(4):404-6.
Archer SM. Are amblyopia treatments
really all equal? Is that even the right
question? Am Orthopt J. 2012;62:1-3.
Benetz BA, Lass JH, Gal RL, Sugar A,
Menegay H, Dontchev M, Kollman C,
Beck RW, Mannis MJ, Holland EJ,
Gorovoy M, Hannush SB, Bokosky JE,
Caudill JW. Endothelial morphometric
measures to predict endothelial graft
failure after penetrating keratoplasty.
JAMA Ophthalmol. 2013 Mar 14:1-8.
Besirli CG, Elner SG. Retinal vasculitis in
Toxocara canis neuroretinitis. J Ophthalmic
Inflamm Infect. 2013 Jan;3(1):1-3.
36
Besirli CG, Zheng QD, Reed DM,
Zacks DN. ERK-mediated activation
of Fas apoptotic inhibitory molecule 2
(Faim2) prevents apoptosis of 661W
cells in a model of detachment-induced
photoreceptor cell death. PLoS One. 2012
Sep;7(9):e46664.
Bohnsack BL, Freedman SF. Surgical outcomes in childhood uveitic glaucoma. Am
J Ophthalmol. 2013 Jan;155(1):134-42.
Bohnsack BL, Kahana A. Thyroid hormone and retinoic acid interact to regulate
zebrafish craniofacial neural crest development. Dev Biol. 2013 Jan;373(2):300-9.
Branham KE, Othman M, Brumm M,
Karoukis AJ, Atmaca-Sonmez P, Yashar
BM, Schwartz SB, Stover NB, Trzupek K,
Wheaton D, Jennings B, Ciccarelli ML,
Jayasundera KT, Lewis RA, Birch D,
Bennett J, Sieving PA, Andreasson S,
Duncan JL, Fishman GA, Iannaccone A,
Weleber RG, Jacobson SG,
Heckenlively JR, Swaroop A. Mutations
in RPGR and RP2 account for 15% of
males with simplex retinal degenerative
disease. Invest Ophthalmol Vis Sci. 2012
Dec;53(13):8232-7.
Branham KE, Yashar BM. Providing
comprehensive genetic-based ophthalmic
care. Clin Genet. 2013 Aug;84(2):183-9.
Epub 2013 Jun 5.
Bressler NM, Chang TS, Varma R, Suner
I, Lee PP, Dolan CM, Ward J, Ianchulev T,
Fine J. Driving ability reported by neovascular age-related macular degeneration
patients after treatment with ranibizumab.
Ophthalmology. 2013 Jan;120(1):160-8.
Briceño CA, Gupta S, Douglas RS.
Advances in the management of thyroid
eye disease. Int Ophthalmol Clin. 2013
Summer;53(3):93-101.
Chen C, Thompson DA, Koutalos Y.
Reduction of all-trans-retinal in vertebrate
rod photoreceptors requires the combined
action of RDH8 and RDH12. J Biol Chem.
2012 Jul;287(29):24662-70.
Chen SK, Chew KS, McNeill DS, Keeley
PW, Ecker JL, Mao BQ, Pahlberg J, Kim
B, Lee SC, Fox MA, Guido W, Wong KY,
et al. Apoptosis regulates ipRGC spacing
necessary for rods and cones to drive
circadian photoentrainment. Neuron.
2013 Feb 6;77(3):503-15.
Chi SL, Acquah KF, Richard MJ, Lee PP,
Sloan FA. Longitudinal evidence on
punctal plug use in an elderly population.
Ophthal Plast Reconstr Surg. 2012
Jul-Aug;28(4):289-93.
Chinskey ND, Cornblath WT. Inferior
oblique myokymia: A unique ocular
motility disorder. JAMA Ophthalmol. 2013
Mar 1;131(3):404-5.
Chou CF, Zhang X, Crews JE, Barker LE,
Lee PP, Saaddine JB. Impact of geographic density of eye care professionals on eye
care among adults with diabetes. Ophthalmic Epidemiol. 2012 Dec;19(6):340-9.
Churchill JD, Bowne SJ, Sullivan LS, Lewis
RA, Wheaton DK, Birch DG, Branham
KE, Heckenlively JR, Daiger SP. Mutations
in the X-linked retinitis pigmentosa genes
RPGR and RP2 found in 8.5% of families
with a provisional diagnosis of autosomal
dominant retinitis pigmentosa. Invest Ophthalmol Vis Sci. 2013 Feb;54(2):1411-6.
Day S, Acquah K, Platt A, Lee PP,
Mruthyunjaya P, Sloan FA. Association
of vitamin D deficiency and age-related
macular degeneration in medicare
beneficiaries. Arch Ophthalmol. 2012
Aug;130(8):1070-1.
July 1, 2012 — June 30, 2013
De Lott LB, Trobe JD, Parmar H. Restricted diffusion of the superior and inferior ophthalmic veins in cavernous sinus
thrombosis. J Neuroophthalmol. 2013
Sep;33(3):268-70. Epub 2013 May 29.
Eggenberger E, Cornblath WT.
“Blinding” empty sella. Arch Neurol.
2012 Aug;69(8):1083-4.
Fante RJ, Shtein RM, Titus MS, Woodward
MA. Anterior segment optical coherence
tomography versus ultrasound pachymetry
to measure corneal thickness in endothelial keratoplasty donor corneas. Cornea.
2013 May;32(5):e79-82.
Farjo AA, Sugar A, Schallhorn SC,
Majmudar PA, Tanzer DJ, Trattler WB,
Cason JB, Donaldson KE, Kymionis GD.
Femtosecond lasers for LASIK flap creation: A report by the American Academy
of Ophthalmology. Ophthalmology. 2013
Mar;120(3):e5-20.
Field MG, Comer GM, Kawaji T, Petty
HR, Elner VM. Noninvasive imaging of
mitochondrial dysfunction in dry agerelated macular degeneration. Ophthalmic Surg Lasers Imaging. 2012 SepOct;43(4):358-65.
Fox TE, Young MM, Pedersen MM, Han
X, Gardner TW, Kester M. Diabetes
diminishes phosphatidic acid in the retina:
A putative mediator for reduced mTOR
signaling and increased neuronal cell
death. Invest Ophthalmol Vis Sci. 2012
Oct;53(11):7257-67.
Fritsche LG, Chen W, Schu M, Yaspan BL,
Yu Y, Thorleifsson G, Zack DJ, Arakawa S
...Branham KE...Heckenlively JR, et al.
Seven new loci associated with age-related
macular degeneration. Nat Genet 2013
Apr;45(5):433-9.
Gillespie EF, Raychaudhuri N,
Papageorgiou KI, Atkins SJ, Lu Y,
Charara LK, Mester T, Smith TJ, Douglas
RS. Interleukin-6 (IL-6) production in
CD40-engaged fibrocytes in thyroidassociated ophthalmopathy: Involvement
of Akt and NF-kappaB. Invest Ophthalmol
Vis Sci. 2012 Nov;53(12):7746-53.
Goldstein JE, Massof RW, Deremeik JT,
Braudway S, Jackson ML, Kehler KB, Primo
SA, Sunness JS; Low Vision Research Network Study Group. Baseline traits of low
vision patients served by private outpatient
clinical centers in the United States. Arch
Ophthalmol 2012 Aug;130(8):1028-37.
[Wicker DM, Day SH - Collaborators]
Greene JB, Mian SI. Cataract surgery in
patients with corneal disease. Curr Opin
Ophthalmol. 2013 Jan;24(1):9-14.
Gupta S, Briceño CA, Douglas RS.
Customized minimally invasive orbital
decompression for thyroid eye disease.
Expert Review of Ophthalmology. 2013
Jun;8(3):255-66.
Hahn P, Acquah K, Cousins SW, Lee PP,
Sloan FA. Ten-year incidence of agerelated macular degeneration according to
diabetic retinopathy classification among
Medicare beneficiaries. Retina. 2013
May;33(5):911-9.
Harris Nwanyanwu KM, De Lott LB,
Cornblath WT, Elner VM. Transient
monocular vision loss due to churg-strauss
syndrome vasculitis. JAMA Ophthalmol.
2013 Jan;131(1):117-9.
Hood CT, Krueger RR, Wilson SE. The
association between femtosecond laser
flap parameters and ocular aberrations
after uncomplicated custom myopic LASIK.
Graefes Arch Clin Exp Ophthalmol. 2013
Sep;251(9):2155-62. Epub 2013 Apr 9.
Hood CT, Shtein RM, Mian SI, Sugar A.
Neodymium-yttrium-aluminum-garnet laser
lysis of retained cortex after phacoemulsification cataract surgery. Am J Ophthalmol.
2012 Nov;154(5):808-13.
Hu C, Hill DD, Wong KY. Intrinsic
physiological properties of the five types
of mouse ganglion-cell photoreceptors.
J Neurophysiol. 2013 Apr;109(7):187689.
Igo RP Jr, Kopplin LJ, Joseph P, Truitt B,
Fondran J, Bardenstein D, Aldave AJ, et al.
FECD Genetics Multi-Center Study Group.
Differing roles for TCF4 and COL8A2 in
central corneal thickness and Fuchs endothelial corneal dystrophy. PLoS One. 2012
Oct;7(10):e46742. [Soong HK,
Sugar A, Mian SI - Collaborators]
Johnson MW. Conclusion. Retina. 2012
Sep;32 Suppl 2:S232.
Johnson MW. How should we release
vitreomacular traction: Surgically, pharmacologically, or pneumatically? Am J
Ophthalmol. 2013 Feb;155(2):203-5 e1.
Johnson MW. Myopic traction maculopathy: Pathogenic mechanisms and surgical
treatment. Retina. 2012 Sep;32 Suppl
2:S205-10.
Johnson MW. Posterior vitreous detachment: Evolution and role in macular
disease. Retina. 2012 Sep;32 Suppl
2:S174-8.
Kahana A, Lee BJ, Flint A, Elner VM.
Periocular epithelioid hemangioma:
Response to bevacizumab and vascular
pathogenesis. Arch Ophthalmol. 2012
Sep;130(9):1209-12.
Kalyani PS, Chinskey N, Schneider
E, Besirli CG, Zacks DN. Intraocular tooth. JAMA Ophthalmol. 2013
Feb;131(2):241.
37
July 1, 2012 — June 30, 2013
Kassa E, Elner VM, Moroi SE, Sun Y.
Diffuse Berlin nodules: Unusual presentation of ocular sarcoidosis. Br J Ophthalmol.
2013 Sep;97(9):1214. Epub 2013
May 31.
Kaufman SC, Jacobs DS, Lee WB, Deng
SX, Rosenblatt MI, Shtein RM. Options
and adjuvants in surgery for pterygium:
A report by the American Academy of
Ophthalmology. Ophthalmology. 2013
Jan;120(1):201-8.
Keil JM, Liu X, Antonetti DA. Glucocorticoid induction of occludin expression and
endothelial barrier requires transcription
factor p54 NONO. Invest Ophthalmol
Vis Sci. 2013 Jun;54(6):4007-15.
Kempen JH, Sugar EA, Jaffe GJ,
Acharya NR, Dunn JP, Elner SG, Lightman
SL, Thorne JE, Vitale AT, Altaweel MM.
Fluorescein angiography versus optical
coherence tomography for diagnosis of
uveitic macular edema. Ophthalmology.
2013 Sep;120(9):1852-9. Epub 2013
May 21.
Krom MM, Zacks DN, Vrabec JP. Late-onset cystoid macular edema as a presenting
symptom of anca-negative pauciimmune
crescentic glomerulonephritis. Retinal cases
& brief reports. 2012 Fall;6(4):368-70.
Kron M, Bohnsack BL, Archer SM,
McHugh JB, Kahana A. Recurrent orbital
schwannomas: clinical course and histopathologic correlation. BMC Ophthalmol.
2012 Aug;12(1):44.
Kymes SM, Lambert DL, Lee PP, Musch
DC, Siegfried CJ, Kotak SV, Stwalley DL,
Fain J, Johnson C, Gordon MO. The development of a decision analytic model of
changes in mean deviation in people with
glaucoma: The COA model. Ophthalmology. 2012 Jul;119(7):1367-74.
38
Laird PW, Woodward MA, Williams JG,
Lee WB, Grossniklaus HE. Cystic benign
melanosis of the conjunctiva. Cornea.
2012 Nov;31(11):1273-7
Lee BJ, Nelson CC, Lewis CD, Perry JD.
External dacryocystorhinostomy surgery
in patients with Wegener granulomatosis.
Ophthal Plast Reconstr Surg. 2012 NovDec;28(6):389-92.
Lee PP, West SK, Block SS. Surveillance of
disparities in vision and eye health in the
United States: An expert panel’s opinions. Am J Ophthalmol. 2012 Dec;154(6
suppl):S3-S7.
Leinberger RL, Janz NK, Musch DC, Niziol
LM, Gillespie BW. Discussing driving
concerns with older patients: I. vision care
providers’ attitudes and behaviors. JAMA
Ophthalmol 2013 Feb;131(2):205-12.
Lichter PR, Bartley GB. Interview with
Paul R. Lichter, MD. Arch Ophthalmol.
2012 Sep;130(9):1205-6.
Lott ME, Slocomb JE, Shivkumar V, Smith
B, Gabbay RA, Quillen D, Gardner TW,
Bettermann K. Comparison of retinal
vasodilator and constrictor responses in
type 2 diabetes. Acta Ophthalmol. 2012
Sep;90(6):e434-41.
Lott ME, Slocomb JE, Shivkumar V, Smith
B, Quillen D, Gabbay RA, Gardner TW,
Bettermann K. Impaired retinal vasodilator responses in prediabetes and type
2 diabetes. Acta Ophthalmol 2013
Sep;91(6):e462-9. Epub 2013 Jun 7.
Lu Y, Vitart V, Burdon KP, Khor CC,
Bykhovskaya Y, Mirshahi A, Hewitt AW
...Richards JE, Moroi SE, et al. Genomewide association analyses identify multiple
loci associated with central corneal thickness and keratoconus. Nat Genet. 2013
Feb;45(2):155-63.
Luo J, Uribe RA, Hayton S, Calinescu
AA, Gross JM, Hitchcock PF. Midkine-A
functions upstream of Id2a to regulate cell
cycle kinetics in the developing vertebrate
retina. Neural Dev. 2012 Oct;7(1):33.
Marmor MF, Chien FY, Johnson MW.
Value of red targets and pattern deviation
plots in visual field screening for hydroxychloroquine retinopathy. Arch Ophthalmol.
2013 Apr;131(4):476-80.
Mendoza-Reinoso V, Patil TS, GuevaraFujita ML, Fernandez S, Vargas E, CastilloHerrera W, Perez-Grossmann R, LizarasoCaparo F, Richards JE, Fujita R. Novel
and known MYOC exon 3 mutations in
an admixed Peruvian primary open-angle
glaucoma population. Mol Vis. 2012 Aug
8;18:2067-75.
Mets MB, Rich WL, Lee PP, Schuman
JS, Wilson D, Chew E, Buckley E. The
Ophthalmic Practice of the Future. Arch
Ophthalmol 2012 Sep;130(9):1195-8.
Mizrachi IB, Trobe JD. [Cavernous hemangioma of anterior visual pathways — a
rare cause of visual loss]. Harefuah. 2013
Feb;152(2):92-7, 123.
Muir KW, Gupta C, Gill P, Stein JD. Accuracy of international classification of
diseases, ninth revision, clinical modification billing codes for common ophthalmic
conditions. JAMA Ophthalmol. 2013
Jan;131(1):119-20.
Musch DC, Gardner TW. Diabetes and
nonrefractive visual impairment: The young
have it. JAMA. 2012 Dec;308(22):2403-4.
Musch DC, Janz NK, Leinberger RL,
Niziol LM, Gillespie BW. Discussing
driving concerns with older patients:
II. vision care providers’ approaches to
assessment. JAMA Ophthalmol. 2013
Feb;131(2):213-8.
July 1, 2012 — June 30, 2013
Musch DC, Shimizu T, Niziol LM, Gillespie
BW, Cashwell LF, Lichter PR. Clinical
characteristics of newly diagnosed primary, pigmentary and pseudoexfoliative
open-angle glaucoma in the Collaborative
Initial Glaucoma Treatment Study. Br J
Ophthalmol. 2012 Sep;96(9):1180-4.
Newman-Casey PA, Weizer JS, Heisler
M, Lee PP, Stein JD. Systematic review
of educational interventions to improve
glaucoma medication adherence. Semin
Ophthalmol. 2013 May;28(3):191-201.
Niziol LM, Musch DC, Gillespie BW,
Marcotte LM, Sugar A. Long-term outcomes in patients who received a corneal graft for keratoconus between 1980
and 1986. Am J Ophthalmol. 2013
Feb;155(2):213-9.e3.
Nwanyanwu KH, Comer GM, Demirci H.
Presumed choroidal metastasis secondary
to clear cell sarcoma of the right knee.
Int Ophthalmol. 2013 Apr;33(2):163-5.
Harris Nwanyanwu K, Talwar N, Gardner
TW, Wrobel JS, Herman WH, Stein JD.
Predicting development of proliferative
diabetic retinopathy. Diabetes Care 2013
Jun;36(6):1562-8.
Ou Y, Grossman DS, Lee PP, Sloan FA.
Glaucoma, Alzheimer disease and other
dementia: a longitudinal analysis. Ophthalmic Epidemiol. 2012 Oct;19(5):285-92.
Padmaja S, Cornblath WT. Oculopalatal
tremor in multiple sclerosis with spontaneous resolution. Neurol Clin Pract. 2012
Sep;2(3):255-57.
Pasquale LR, Loomis SJ, Kang JH, Yaspan
BL, Abdrabou W, Budenz DL, Chen TC
...Lichter PR, Liu Y, McCarty CA, Moroi
SE...Richards JE, Haines JL, Wiggs JL.
CDKN2B-AS1 Genotype-glaucoma feature
correlations in primary open-angle glaucoma patients from the United States. Am
J Ophthalmol. 2013 Feb;155(2):342-53.
Paz SH, Slotkin J, McKean-Cowdin R,
Lee PP, Owsley C, Vitale S, Varma R,
Gershon R, Hays RD. Development of a
vision-targeted health-related quality of life
item measure. Qual Life Res. Epub 2013
Mar 9.
Peeler C, Parmar H, Trobe JD. Subretinal
abscess causing restricted diffusion on
magnetic resonance imaging. J Neuroophthalmol. Epub 2013 Jun 18.
Ple-Plakon PA, Demirci H, Cheng JX, Elner
VM. Orbital myeloid sarcoma in an adult
with acute myeloid leukemia, FAB M1, and
12p- deletion. Ophthal Plast Reconstr Surg.
2013 May-June;29(3):e73-5.
Prabhu SS, Kaakeh R, Sugar A, Smith DG,
Shtein RM. Comparative cost-effectiveness
analysis of descemet stripping automated
endothelial keratoplasty versus penetrating keratoplasty in the United States. Am J
Ophthalmol. 2013 Jan;155(1):45-53.
Rumery TC, Mian SI. Ocular graft vs.
host disease after hematopoietic stem
cell transplantation. Insight. 2013
Winter;38(1):11-8.
Runkle EA, Rice SJ, Qi J, Masser D,
Antonetti DA, Winslow MM, Mu D.
Occludin is a direct target of thyroid transcription factor-1 (TTF-1/NKX2-1). J Biol
Chem. 2012 Aug;287(34):28790-801.
Schachar IH, Zahid S, Comer GM, Stem
M, Schachar AG, Saxe SJ, Gardner TW,
Elner VM, Jayasundera KT. Quantification of fundus autofluorescence to detect
disease severity in nonexudative agerelated macular degeneration. JAMA
Ophthalmol. 2013 Aug;131(8):1009-15.
Epub 2013 Jun 20.
Schneider EW, Elner SG, van Kuijk FJ,
Goldberg N, Lieberman RM, Eliott D,
Johnson MW. Chronic retinal necrosis:
Cytomegalovirus necrotizing retinitis
associated with panretinal vasculopathy in non-HIV patients. Retina. 2013
Oct;33(9):1791-9 . Epub 2013 April 16.
Shelby SJ, Colwill K, Dhe-Paganon S,
Pawson T, Thompson DA. MERTK interactions with SH2-domain proteins in the
retinal pigment epithelium. PLoS One.
2013 Feb;8(2):e53964.
Shi D, Funayama T, Mashima Y, Takano
Y, Shimizu A, Yamamoto K, Mengkegale
M, Miyazawa A, Yasuda N, Fukuchi T,
Abe H, Ideta H, Nishida K, Nakazawa T,
Richards JE, Fuse N. Association of HK2
and NCK2 with normal tension glaucoma
in the Japanese population. PLoS One.
2013 Jan;8(1):e54115.
Shtein RM, Callaghan BC. Corneal
confocal microscopy as a measure of
diabetic neuropathy. Diabetes. 2013
Jan;62(1):25-6.
Shtein RM, Michelotti MM, Kaplan A,
Mian SI. Association of surgeon experience with outcomes of femtosecond LASIK.
Ophthalmic Surg Lasers. Imaging 2012
Nov-Dec;43(6):489-94.
Shtein RM, Raoof-Daneshvar D, Lin HC,
Sugar A, Mian SI, Nan B, Stein JD.
Keratoplasty for corneal endothelial
disease, 2001-2009. Ophthalmology.
2012 Jul;119(7):1303-10.
Shtein RM, Raoof-Daneshvar D, Lin HC,
Sugar A, Mian SI, Nan B, Stein JD.
Author reply. Ophthalmology. 2013
Mar;120(3):650-1
Smith TJ. Is IGF-I receptor a target for
autoantibody generation in Graves’
disease? J Clin Endocrinol Metab. 2013
Feb;98(2):515-8.
39
July 1, 2012 — June 30, 2013
Soong HK, de Melo Franco R. Anterior
chamber gas bubbles during femtosecond laser flap creation in LASIK: Video
evidence of entry via trabecular meshwork. J Cataract Refract Surg. 2012
Dec;38(12):2184-5.
Stem MS, Talwar N, Comer GM, Stein
JD. A longitudinal analysis of risk
factors associated with central retinal
vein occlusion. Ophthalmology. 2013
Feb;120(2):362-70.
Spielberg LH, Heckenlively JR, Leys AM.
Retinal pigment epithelial detachments and
tears, and progressive retinal degeneration in light chain deposition disease. Br J
Ophthalmol. 2013 May;97(5):627-31.
Stulting RD, Sugar A, Beck R, Belin M,
Dontchev M, Feder RS, Gal RL, Holland
EJ, Kollman C, Mannis MJ, Price F, Jr.,
Stark W, Verdier DD. Effect of donor and
recipient factors on corneal graft rejection.
Cornea. 2012 Oct;31(10):1141-7.
Stein JD, Childers DM, Nan B, Mian SI.
Gauging interest of the general public in
laser-assisted in situ keratomileusis eye
surgery. Cornea. 2013;32(7):1015-8.
Sudhakar P, Parmar H, Cornblath WT.
Oculopalatal tremor in multiple sclerosis
with spontaneous resolution. Neurol Clin
Pract. 2012 Sep;2(3):255-7.
Stein JD, Hanrahan BW, Comer GM,
Sloan FA. Diffusion of technologies for
the care of older adults with exudative
age-related macular degeneration. Am J
Ophthalmol. 2013 Apr;155(4):688-96.
Sudhakar P, Trobe JD, Wesolowski J.
Dural puncture-induced intracranial hypotension causing diplopia. J Neuroophthalmol. 2013 Jun;33(2):106-12.
Stein JD, Newman-Casey PA, Kim DD,
Nwanyanwu KH, Johnson MW, Hutton
DW. Cost-effectiveness of various interventions for newly diagnosed diabetic
macular edema. Ophthalmology. 2013
Sep;120(9):1835-42. Epub 2013 May 1.
Stein JD, Newman-Casey PA, Talwar N,
Nan B, Richards JE, Musch DC. The
relationship between statin use and
open-angle glaucoma. Ophthalmology.
2012 Oct;119(10):2074-81.
Stein JD, Niziol LM, Musch DC, Lee PP,
Kotak SV, Peters CM, Kymes SM. Longitudinal trends in resource use in an incident
cohort of open-angle glaucoma patients:
Resource use in open-angle glaucoma.
Am J Ophthalmol. 2012 Sep;154(3):4529 e2.
Stein JD, Talwar N, Laverne AM, Nan B,
Lichter PR. Racial disparities in the use of
ancillary testing to evaluate individuals
with open-angle glaucoma. Arch Ophthalmol. 2012 Dec;130(12):1579-88.
40
Tash BR, Bewley MC, Russo M, Keil JM,
Griffin KA, Sundstrom JM, Antonetti DA,
Tian F, Flanagan JM. The occludin and
ZO-1 complex, defined by small angle
X-ray scattering and NMR, has implications for modulating tight junction permeability. Proc Natl Acad Sci U S A. 2012
Jul;109(27):10855-60.
Taylor S, Chen J, Luo J, Hitchcock PF.
Light-induced photoreceptor degeneration
in the retina of the zebrafish. Methods Mol
Biol. 2012;884:247-54.
Thompson DA., Klionsky DJ. Autophagy
and gene therapy combine in the treatment
of liver disease. Autophagy. 2013 Apr
16;9(7).
Titchenell PM, Antonetti DA. Using
the past to inform the future: Anti-VEGF
therapy as a road map to develop novel
therapies for diabetic retinopathy.
Diabetes. 2013 Jun;62(6):1808-15.
Titchenell PM, Hollis Showalter HD,
Pons JF, Barber AJ, Jin Y, Antonetti DA.
Synthesis and structure-activity relationships of 2-amino-3-carboxy-4-phenylthiophenes as novel atypical protein kinase
C inhibitors. Bioorg Med Chem Lett. 2013
May;23(10):3034-8.
Titchenell PM, Lin CM, Keil JM, Sundstrom
JM, Smith CD, Antonetti DA. Novel
atypical PKC inhibitors prevent vascular
endothelial growth factor-induced bloodretinal barrier dysfunction. Biochem J.
2012 Sep;446(3):455-67.
Trobe JD. The scholarly contributions of
Daniel M. Jacobson, MD. J Neuroophthalmol. 2012 Dec;32(4):372-8.
Ulmer M, Li J, Yaspan BL, Ozel AB,
Richards JE, Moroi SE...Lichter PR, et al.
Genome-wide analysis of central corneal
thickness in primary open-angle glaucoma
cases in the NEIGHBOR and GLAUGEN
consortia. Invest Ophthalmol Vis Sci. 2012
Jul;53(8):4468-74.
Vanderbeek BL, Zacks DN, Talwar N,
Nan B, Stein JD. Role of statins in the
development and progression of age-related macular degeneration. Retina. 2013
Feb;33(2):414-22.
Varma R, Bressler NM, Suner I, Lee PP,
Dolan CM, Ward J, Colman S, Rubio RG.
Improved vision-related function after ranibizumab for macular edema after retinal
vein occlusion: Results from the BRAVO
and CRUISE trials. Ophthalmology. 2012
Oct;119(10):2108-18.
Verdier DD, Sugar A, Baratz K, Beck R,
Dontchev M, Dunn S, Gal RL, Holland EJ,
Kollman C, Lass JH, Mannis MJ, Penta
J. Corneal thickness as a predictor of
corneal transplant outcome. Cornea. 2013
Jun;32(6):729-36.
July 1, 2012 — June 30, 2013
Verhoeven VJ, Hysi PG, Wojciechowski R,
Fan Q, Guggenheim JA, Hohn R,
MacGregor S, et al. Genome-wide metaanalyses of multiancestry cohorts identify
multiple new susceptibility loci for refractive error and myopia. Nat Genet 2013
Mar;45(3):314-8. [Comer GM, Elner SG,
Gardner TW, Hackel R, Mian SI,
Soong HK, Sugar A - Collaborators]
Wang I, Khan NW, Branham KE, Wissinger B, Kohl S, Heckenlively JR. Establishing baseline rod electroretinogram values
in achromatopsia and cone dystrophy.
Doc Ophthalmol Epub 2012 Aug 19.
Weizer JS, Musch DC, Niziol LM, Khan
NW. Multifocal visual evoked potentials
for early glaucoma detection. Ophthalmic
Surg Lasers Imaging. 2012 Jul;43(4):33540.
West SK, Lee PP. Vision surveillance in
the United States: Has the time come?
Am J Ophthalmol. 2012 Dec;154(6
suppl):S1-S2.
Wiggs JL, Hauser MA, Abdrabou W,
Allingham RR, Budenz DL, Delbono E,
Friedman DS, Kang JH, Gaasterland D,
Gaasterland T, Lee RK, Lichter PR, Loomis
S, Liu Y, McCarty C, Medeiros FA, Moroi
SE, Olson LM, Realini A, Richards JE,
Rozsa FW, Schuman JS, Singh K, Stein
JD, Vollrath D, Weinreb RN, Wollstein G,
Yaspan BL, Yoneyama S, Zack D, Zhang
K, Pericak-Vance M, Pasquale LR,
Haines JL. The NEIGHBOR Consortium
Primary Open-Angle Glaucoma Genomewide Association Study: Rationale, study
design, and clinical variables. J Glaucoma
2013 Sep;22(7):517-25. Epub 2012
July 26.
Wilkinson JE, Burmeister L, Brooks SV,
Chan CC, Friedline S, Harrison DE,
Hejtmancik JF, Nadon N, Strong R,
Wood LK, Woodward MA, Miller RA.
Rapamycin slows aging in mice.
Aging Cell. 2012 Aug;11(4):675-82.
Wong KY. A retinal ganglion cell
that can signal irradiance continuously for 10 hours. J Neurosci 2012
Aug;32(33):11478-85.
Woodward MA, Raoof-Daneshvar D,
Mian SI, Shtein RM. Relationship of visual
acuity and lamellar thickness in descemet
stripping automated endothelial keratoplasty. Cornea. 2013 May;32(5):e69-73.
Zhang XJ, Liang YB, Liu YP, Jhanji V,
Musch DC, Peng Y, Zheng CR, Zhang HX,
Chen P, Tang X, Lam DS. Implementation
of a free cataract surgery program in rural
China: A community-based randomized
interventional study. Ophthalmology. 2013
Feb;120(2):260-5.
Zhang L, Weizer JS. Sequential glaucoma
drainage devices for high intraocular pressure. Glaucoma Today. 2012 Nov-Dec.
Zhang W, Zhang X, Wang H, Sharma
AK, Hughes BA. Characterization of the
R162W Kir7.1 mutation associated with
snowflake vitreoretinopathy. Am J Physiol
Cell Physiol. 2013 Mar;304(5):C440-9.
Woodward MA, Ross KW, Requard JJ,
Sugar A, Shtein RM. Impact of surgeon
acceptance parameters on cost and
availability of corneal donor tissue
for transplantation. Cornea. 2013
Jun;32(6):737-40.
Yue H, Qian J, Elner VM, Guo J, Yuan
YF, Zhang R, Ge Q. Treatment of orbital
vascular malformations with intralesional
injection of pingyangmycin. Br J Ophthalmol. 2013 Jun;97(6):739-45.
Zahid S, Jayasundera KT, Rhoades W,
Branham KE, Khan NW, Niziol LM,
Musch DC, Heckenlively JR. Clinical phenotypes and prognostic full-field electroretinographic findings in Stargardt disease.
Am J Ophthalmol. 2013 Mar;155(3):46573.
Zahid S, Musch DC, Niziol LM, Lichter
PR. Risk of endophthalmitis and other
long-term complications of trabeculectomy
in the Collaborative Initial Glaucoma
Treatment Study (CIGTS). Am J Ophthalmol. 2013 Apr;155(4):674-80.
41
External grants and Funding
July 1, 2012 — June 30, 2013
Facult y Name
S ource
ID P roject Title
S. Abcouwer, Ph.D.
NIH
R01-EY020582-05
Regulation of Retinal Cell Death in Diabetes; Co-PI
NIH
R01-EY007739
Bone Marrow Neuropathy Drives Diabetic Retinopathy,
Subcontract with University of Florida;
PI: Maria Bartolomeo Grant, M.D.
JDRF
JDRF Center for Mechanisms and Intervention
of Diabetic Retinopathy; Project 2 Co-PI
JDRF
Testing the Role of A3AR in Diabetic Retinopathy Pathologies
D. Antonetti, Ph.D.
NIH
R01-EY-012021-16 Mechanisms of Retinal Vascular Permeability in Diabetes
NIH
R01-EY-021165
The Retinal Microenvironment in Diabetic Retinopathy
Subcontract with Northwestern University,
PI: Robert Linsenmeier, Ph.D.
NIH
R01-GM094526
Structural Studies of Tight Junction Proteins,
Subcontract with Pennsylvania State University,
PI: John M. Flanagan, Ph.D.
JDRF
Targeting aPKC as a Therapy for Diabetic Retinopathy
JDRF
JDRF Center for Mechanisms and Intervention
of Diabetic Retinopathy; Project 2 Co-PI
JDRF
PolyChromatic Angiography for Grading Retinal
Vascular Leakage
RPB
Jules and Doris Stein RPB Professorship
B. Bohnsack, M.D., Ph.D. NIH
K08-EY022912-01 Regulation of Ocular Neural Crest and Its Implications in
Congenital Eye Diseases
RPB
A Zebrafish Model for Congenital Eye Diseases
G. Comer, M.D., M.S. LMRI/ Clinical Trial
A Natural History Study of Macular Telangiectasia —
The MacTel Study
JDRF
Structural and Functional Relationships of the Retina in
Diabetic Macular Edema
M. Del Monte, M.D.
Alcon Laboratories, Inc.
A 3-month, Multi-Center, Double-Masked Safety and Efficacy
Study of Travoprost Ophthalmic Solution, 0.004% Compared
to Timolol (0.5% or 0.25%) in Pediatric Glaucoma Patients
Alcon Laboratories, Inc.
An Open-Label, Pharmacokinetic and Safety Study of Travoprost
Ophthalmic Solution, 0.004% in Pediatric Glaucoma or
Ocular Hypertension Patients
H. Demirci, M.D.
Midwest Eye-Banks
Roles of Inflammation and Angiogenesis in Conjunctival
Melanoma: Progression and Metastasis
R. Douglas, M.D., Ph.D. NIH
R01-EY211197-03
Role of CD40+ Fibrocytes in Thyroid-Associated
Ophthalmopathy
42
July 1, 2012 — June 30, 2013
Facult y Name
S ource
ID P roject Title
R. Douglas, M.D., Ph.D. River Vision LLC
A Multicenter, Double-Masked, Placebo-Controlled, Efficacy and
(cont.) Safety Study of RV001, an Insulin-like Growth Factor-1
Receptro (IGF-1R) Antagonist Antibody (fully human),
Administered Every 3 Weeks (Q3W) by Intravenous (IV) Infusion
in Patients Suffering from Active Thyroid Eye Disease (TED)
RPB
Lew R. Wasserman Merit Award
S. Elner, M.D.
NIH/Clinical Trial
U01-EY014660-06 Multicenter Uveitis Steroid Treatment (MUST) Trial
Coordinating Center: Johns Hopkins University
Santen Pharmeceutical
Intravitreal Injections of DE-109 for the Treatment of Active,
Non-Infectious Uveitis
P. Fort, Ph.D.
NIH
R01-EY020895-01
Progressive Impact of Diabetes on Retinal Neuroprotection by
α-Crystallins
Midwest Eye-Banks
Characterization of Crystallin Proteins Expression in Human Retina:
Effect of Diabetes
Fight for Sight
Detailed Analysis of Crystallins Cellular and Sub-cellular
Upregulation during Diabetic Retinopathy
P. Gage, Ph.D.
NIH
R01-EY014126-10
Pitx 2: Molecular Mechanisms in Eye Development and Disease
T. Gardner, M.D., M.S. NIH
R01-EY020582-05
Regulation of Retinal Cell Death in Diabetes; Co-PI
NIH
DP3-DK094292-02 Metabolic Reprogramming in Diabetic Complications; Co-PI
Subaccount with Frank C. Brosius, M.D., Department of
Nephrology, University of Michigan
NIH
K12-EY022299-01A1 Michigan Vision Clinician-Scientist Development Program; Co-PI
NIH/Clinical Trial
U10-EY14231
Prompt Panretinal Photocoagulation (Protocol S),
Coordinating Center: Jaeb
NIH/Clinical Trial
U10-EY01423
Genes in Diabetic Retinopathy, Coordinating Center: Jaeb
American Diabetes Association
Evaluation of Diabetic Retinal Sensory Neuropathy
JDRF
JDRF Center for Mechanisms and Intervention of
Diabetic Retinopathy
JDRF
Evaluation of Retinal Sensory Neuropathy
Midwest Eye-Banks
A Diabetic Retinopathy Risk of Progression Calculator
RPBPhysician-Scientist Award
J. Heckenlively, M.D. NIH
R21-EY022172-02
Investigation of Autoimmune Anti-Retinal Antibodies in Diabetes
FFB
Center for the Study of Retinal Degenerative Diseases
The Juliette Retinitis Pigmentosa (RP) Foundation X-Chromosome Inactivation Ratios and Variable Expressivity in
Heterozygotic Female Carriers of RPGR Mutations
Award for Abigail Fahim, M.D., Ph.D.
NNRI
NNSP-CL-0212-
A Phase II Multiple Site, Randomized, Placebo-Controlled
0061-MICH-NER Trial of Oral Valproic Acid for Retinitis Pigmentosa
P. Hitchcock, Ph.D.
NIH
NIH
NIH
R01-EY007060-23
Neuronal Development, Injury and Repair in Retina
T32-EY013934-11Vision Research Training Program
F32-EY023129-01
NRSA Postdoctoral Fellowship for Scott Taylor, Ph.D.
43
July 1, 2012 — June 30, 2013
Facult y Name
S ource
ID P roject Title
B. Hughes, Ph.D.
NIH
NIH
P30-EY007003-26
R01-EY008850-22
Core Center for Vision Research (five core modules)
Ion Conductances in the Retinal Pigment Epithelium
T. Jayasundera, M.D.
Alliance for Vision Research
Quantification of Macular Autofluorescence in
Dry Age-Related Macular Degeneration
Fight for Sight
Quantification of Changes in Macular Autofluorescence in
Dry Age-Related Macular Degeneration
Midwest Eye-Banks
Novel Quantification Methods for Fundus Flavoprotein
Fluorescence and Lipofuscin Fluorescence to Detect
Progression in Stargardt Disease
A. Kahana, M.D., Ph.D. NIH
R01-EY022633-01A1 A Zebrafish Model of Extraocular Muscle Regeneration
Biological Signals Controlling Extraocular Muscle Regeneration
Chemical Genomic Screen for Modifiers of Axenfeld-Rieger
Syndrome: A Pilot Study to Identify Novel Therapeutics
of Anterior Segment Dysgenesis
Investigating the Role of Extracellular Matrix Factors and
Collective Cell Migration in Extraocular Muscle Repair
and Regeneration Using a Zebrafish Model
Investigating the Roles of Retinoic Acid and Thyroid Hormone in
the Pathogenesis of Thyroid Eye Disease
Investigating the Roles of Twist1 and Twist2 in Extraocular
Muscle Biology and Orbital Rhabdomyosarcoma
Alliance for Vision Research Regulation of Extraocular Muscle Response to Injury by
Autophagy and Extracellular Matrix Remodeling, Possible
Targets for Therapy
Thyroid-Related Eye Disease: A Preclinical Study Investigating
the Role of Retinoid Receptors in Mediating Orbitopathy
Midwest Eye-Banks
Chemical Genomic Screen for Modifiers of
Axenfeld-Rieger Syndrome
RPB
Career Development Award
P. Lee, M.D., J.D.
NIH
K12-EY022299-01A1 Michigan Vision Clinician-Scientist Development Program; Co-PI
NIHVision Health Initiative - IPA with CDC
RPB
Unrestricted Grant 2013
W. K. Kellogg Foundation
Child Vision Care Fund
P. Lichter, M.D. RPB
Unrestricted Grant 2012
S. Mian, M.D.
Ocular Findings after Hematopoietic Stem Cell Transplantation
Bausch & Lomb, Inc.
Treatment of Ocular Graft-versus-Host Disease (GVHD)
with Topical Loteprednol Etabonate 0.5%
Midwest Eye-Banks
Eye Bank Preparation of Donor Tissue for Descemet’s Membrane
Endothelial Keratoplasty
Midwest Eye-Banks
Tissue Processing Techniques for Ultra-Thin Descemet’s Stripping
Endothelial Keratoplasty, Award for Maria Woodward, M.D.
44
July 1, 2012 — June 30, 2013
Facult y Name
S ource
ID P roject Title
S. Moroi, M.D., Ph.D. NIH
R01-EY-022124-02 Aqueous Humor Dynamic Components that Determine
Intraocular Pressure Variance
D. Musch, Ph.D., M.P.H. NIH
R21-EY-020912-02 Clinical and Quality of Life Insights on Glaucoma
from Analyses of CIGTS Data
NIH
R34-EY022399-01A1 Statins To Prevent Glaucoma Trial (STOP Glaucoma Trial)
Planning Grant
NIH
R21-EY023452
Factors Predictive of Rapid Visual Field Loss in Early Glaucoma,
Subcontract with Washington University,
Co-PI: Feng Gao, M.D., Ph.D., Mae O. Gordon, Ph.D.
RPB
`
Lew R. Wasserman Award
H. Pawar, Ph.D.
Defining the Anatomical Mechanism of
Canaloplasty Angle Surgery
H. Petty, Ph.D.
Evaluating the Toxicity of Novel Anti-Tumor Nanoparticles in
Animals
Mechanistic Studies of a New Light-Activated Nanoparticle for
Managing Ocular Cancer
Elsa U. Pardee Foundation
Pilot Studies on the Anti-Tumor Capacity of Novel Catalytic
Nanoparticles
D. Puro, M.D., Ph.D. NIH
R01-EY012507-14
Retinovascular Pathophysiology: Focus on
Proliferative Retinopathy
Retinopathy of Prematurity: A New Experimental Approach
J. Richards, Ph.D.
NIH
R01-EY011671-11
NIH
R21 EY021000-02
RPB
Molecular Genetics of Primary Open-Angle Glaucoma
Ocular Effects of Metformin
Senior Scientific Investigator Award
R. Shtein, M.D., M.S. NIH
K23-EY017885-04 Neovascularization Patterns in Corneal Graft Rejection
NIH
P60-DK020572-34 In Vivo Corneal Confocal Microscopy for Non-invasive
Assessment of Diabetic Peripheral Neuropathy; Subaccount
with Michigan Diabetes Research and Training Center,
University of Michigan, Co-PI
Trends in Utilization of Endothelial and Penetrating Keratoplasty
for Treatment of Corneal Endothelial Disease
T. Smith, M.D.
NIH
R01-DK063121-05 Immunoglobulin Activation of Fibroblasts
NIH
R01-EY008976-19
Regulation of Retroocular Connective Tissue
NIH
R01-EY011708-16
Functional Diversity of Orbital Fibroblasts
J. Stein, M.D., M.S.
NIH
K23-EY019511-04 Association between Cataract Surgery and Progression
of Diabetic Retinopathy
NIH
R03-DE022654
Metabolic Syndrome and Periodontitis in Postmenopausal
Women, Subcontract with State University of New York at
Buffalo, PI: Michael J. LaMonte, Ph.D., M.P.H.
45
July 1, 2012 — June 30, 2013
Facult y Name
S ource
ID P roject Title
J. Stein, M.D., M.S.
NIH
R01-AG041776
The Role of Vitamin D in Retinal Diseases in Aging, Subcontract
(cont.) with State University of New York at Buffalo,
PI: Amy E. Millen, Ph.D.
A Diabetic Retinopathy Progression Risk Calculator
American Glaucoma Society
Mentoring for Advancement of Physician-Scientist Enabling
Award Program
Blue Cross Blue Shield of Michigan
Longitudinal Rates of Postoperative Adverse Outcomes
after Glaucoma Surgery among Medicare Beneficiaries
1994–2005
Harvard Medical School
Assessment of the Relation between Medications that
Alter Innate Immunity and Glaucoma
A. Sugar, M.D.
NIH/Clinical Trial
NIH/Clinical Trial
U10-EY012358
U10-EY020797-01
Cornea Donor Study, Coordinating Center: Jaeb
Corneal Preservation Time Study, Coordinating Center: Jaeb
D. Thompson, Ph.D.
FFB
FFB
Gene-Replacement Therapy for XLRP Due to RPGR Mutations
- Continuation
RDH12 Fund for Sight
Gene-Replacement Therapy for RDH12 Mutations
K. Wong, Ph.D.
NIH
R00-EY018863-05
Cross-Talk between Ganglion-Cell Photoreceptors
and Other Neurons in the Retina
Ameliorating the Condition of the Blind through Melanopsin
Midwest Eye-Banks
Functional Characterization of Developmental Changes
in NMDA Receptor Subunit Compostion of Retinal
Ganglion Cells
RPB
Career Development Award
D. Zacks, M.D., Ph.D. NIH
R01-EY020823-04
Autophagy and Control of Photoreceptor Apoptosis
NIH
R43-EY022512
Feasibility Study of ONL-101 for Photoreceptor Neuroprotection
Prevention of Photoreceptor Cell Death with Intravitreal
Fas-receptor Antagonist, Subcontract with ONL Therapeutics,
PI: Jeffrey A. Jamison, Ph.D.
Beckman Foundation
Autophagy and Age-Related Macular Degeneration
FFB
RPB
Sybil B. Harrington Special Scholar Award for
Macular Degeneration
46
Source Abbreviations
FFB
JDRF ................. Juvenile Diabetes Research Foundation International
NIH ................... National Institutes of Health
NNRI ................ National Neurovision Research Institute
NSF ............. National Science Foundation
RPB ............. Research to Prevent Blindness
.................... Foundation
Fighting Blindness
Meet Kellogg’s New Faculty
César A. Briceño, M.D., assistant
professor, has joined the faculty of the
Eye Plastic, Orbital and Facial Cosmetic
Surgery section. Dr. Briceño received
his medical degree from Johns Hopkins
University and then completed his
residency at the Doheny Eye Institute
at the University of Southern California.
In 2013, Dr. Briceño completed a
fellowship in oculoplastics at Kellogg.
He sees patients in our Ann Arbor and
Canton offices.
Lindsey B. De Lott, M.D., clinical lecturer, has joined the faculty of the NeuroOphthalmology section. She earned her
medical degree from Ohio State University
and completed her residency in neurology
at the University of Michigan. In 2013,
Dr. De Lott completed a two-year fellowship in neuro-ophthalmology at Kellogg.
Dr. De Lott sees patients in Kellogg’s Ann
Arbor office and in the Neuro-Ophthalmology suite at U-M Hospital. Read about
Dr. De Lott’s research interests on p.5
Blake V. Fausett, M.D., Ph.D.,
clinical lecturer, has joined the faculty of
the Comprehensive Ophthalmology and
Cataract Surgery section and sees patients
in Kellogg’s Ann Arbor office. Dr. Fausett
earned his medical degree and a Ph.D.
in biochemistry from the University of
Michigan and completed his residency
at Kellogg. In addition to seeing patients,
Dr. Fausett serves as the residency program’s first Graduate Chief Resident.
Jonathan B. Greene, M.D., assistant professor, has joined the faculty of
the Comprehensive Ophthalmology and
Cornea sections. Dr. Greene earned his
medical degree from the University of
Michigan and completed his residency at
the University of California, San Francisco.
In 2013, Dr. Greene completed a fellowship in cornea and refractive surgery at
Kellogg. He sees patients in Ann Arbor.
Vanitha I. Jeyaraj, M.D., clinical
instructor, has joined the faculty of the
Comprehensive Ophthalmology and
Cataract Surgery section and sees patients
in Kellogg’s Milford office. Dr. Jeyaraj
earned her medical degree from the University of Chicago in 2009 and completed
her residency at the Baylor College of
Medicine in 2013.
Paula Anne Newman-Casey, M.D.,
assistant professor, has joined the faculty
of the Glaucoma, Cataract, and Anterior
Segment Disease section and sees patients
in Kellogg’s Canton office. Dr. NewmanCasey earned her medical degree at the
University of Michigan and went on to
complete her residency and a fellowship
in glaucoma at Kellogg. Read about Dr.
Newman-Casey’s research interests on p.4
Rajesh C. Rao, M.D., assistant professor, has joined the faculty of the Retina
and Uveitis section and sees patients
in Kellogg’s Ann Arbor office. Dr. Rao
earned his medical degree at Yale University and completed his residency at
the Massachusetts Eye and Ear Infirmary.
He completed a fellowship in vitreoretinal
surgery at Washington University. Read
about Dr. Rao’s research interests on p.19
Anjali Shah, M.D., clinical instructor,
has joined the faculty of the Retina and
Uveitis section and sees patients in
Kellogg’s Ann Arbor and Brighton offices.
Dr. Shah earned her medical degree from
the University of Michigan and completed
her residency at the Baylor College of
Medicine. She then completed a medical
retina fellowship at the Tufts/New England
Eye Center.
Linda Zhang, M.D., clinical lecturer,
has joined the faculty of the Glaucoma,
Cataract, and Anterior Segment Disease
section and sees patients in Kellogg’s Ann
Arbor and Brighton offices. Dr. Zhang
earned her medical degree at the University of Michigan and then went on to
complete her residency and a fellowship
in glaucoma at Kellogg.
To request an appointment with our new clinicians,
please call 734.763.8122. Referring physicians can
reach these clinicians through M-LINE at 800.962.3555.
47
Faculty of the Department of
Ophthalmology and Visual Sciences – Fall 2013
Leadership
Chair
Alan Sugar, M.D.
Vice Chair
Michael W. Smith-Wheelock, M.D.
Associate Chair for Clinical Affairs
Shahzad I. Mian, M.D.
Associate Chair for Education
Thomas W. Gardner, M.D., M.S.
Associate Chair for Research
Section leaders
Comprehensive Ophthalmology
and Cataract Surgery
Donna M. Wicker, O.D., FAAO
Contact Lens, Low Vision
and Visual Rehabilitation
H. Kaz Soong, M.D.
Cornea and External Disease,
Cataract and Refractive Surgery
Christine C. Nelson, M.D., FACS
Eye Plastic, Orbital and
Facial Cosmetic Surgery
Glaucoma, Cataract and
Anterior Segment Disease
Jonathan D. Trobe, M.D.
Neuro-Ophthalmology
Monte A. Del Monte, M.D.
Pediatric Ophthalmology
and Adult Strabismus
Retina and Uveitis
Adrienne L. West, M.D.
At large
Faculty
Steven F. Abcouwer, Ph.D.
Vision Research
James L. Adams, M.D.
David A. Antonetti, Ph.D.
Vision Research
Steven M. Archer, M.D.
Terry J. Bergstrom, M.D.
Donald S. Beser, M.D., FACS
Cagri G. Besirli, M.D., Ph.D.
Retina and Uveitis
Brenda L. Bohnsack, M.D., Ph.D.
Pediatric Ophthalmology and
Adult Strabismus
Kari E. Branham, M.S., C.G.C.
Genetic Counseling and
Vision Research
César A. Briceño, M.D.
Grant M. Comer, M.D., M.S.
Retina and Uveitis
Theresa M. Cooney, M.D.
Wayne T. Cornblath, M.D.
Neuro-Ophthalmology
Sherry H. Day, O.D., FAAO
Karen S. DeLoss, O.D., FAAO
Lindsey B. De Lott, M.D.
Neuro-Ophthalmology
Hilary M. Grabe, M.D.
Neuro-Ophthalmology
Arivalagan Muthusamy, Ph.D.
Vision Research
Daniel G. Green, Ph.D.
Vision Research
Paula Anne Newman-Casey, M.D., M.S.
Jonathan B. Greene, M.D.
Paul J. Grenier, O.D.
Retina and Uveitis
Peter F. Hitchcock, Ph.D.
Vision Research
Christopher T. Hood, M.D.
Bret A. Hughes, Ph.D.
Vision Research
Ida L. Iacobucci, C.O.
Diane M. Jacobi, O.D.
K. Thiran Jayasundera, M.D.,
FACS, FRCSC, FRANZCO
Retina and Uveitis
Vanitha I. Jeyaraj, M.D.
Hakan Demirci, M.D.
Orbital and Ocular Oncology
Denise A. John, M.D., FRCSC
Courtney A. Dewey, O.D.
Alon Kahana, M.D., Ph.D.
Raymond S. Douglas, M.D., Ph.D.
Ariane D. Kaplan, M.D.
Elizabeth Du, M.D.
Harjeet Kaur, M.D., FRCS(I)
Susan G. Elner, M.D.
Retina and Uveitis
Naheed W. Khan, Ph.D.
Vision Research
Victor M. Elner, M.D., Ph.D.
Jennifer A. Kozak, M.D.
Blake V. Fausett, M.D., Ph.D.
Amy L. Lagina, O.D.
Jerome I. Finkelstein, M.D., FACS
Helios T. Leung, O.D., Ph.D., FAAO
Contact Lens, Low Vision and
Visual Rehabilitation
Patrice E. Fort, Ph.D.
Vision Research
Paul R. Lichter, M.D., FACS
Carlton J. Foster, O.D.
Cheng-mao Lin, Ph.D.
Vision Research
Bruce A. Furr, C.O., Ph.D.
Michael J. Lipson, O.D., FAAO
Philip J. Gage, Ph.D.
Vision Research
Xuwen Liu, M.D., Ph.D.
Vision Research
Christopher Gappy, M.D.
David C. Musch, Ph.D., M.P.H.
Vision Research
Gale A. Oren, M.I.L.S.
Library
Hemant Pawar, Ph.D.
Vision Research
Howard R. Petty, Ph.D.
Vision Research
Donald G. Puro, M.D., Ph.D.
Rajesh C. Rao, M.D.
Retina and Uveitis
Julia E. Richards, Ph.D.
Vision Research
Frank W. Rozsa, Ph.D.
Vision Research
Gary S. Sandall, M.D., FACS
Anjali Shah, M.D.
Retina and Uveitis
Roni M. Shtein, M.D., M.S.
Terry J. Smith, M.D.
Endocrinology
Joshua D. Stein, M.D., M.S.
Bradley W. Taylor, O.D., M.P.H.
Contact Lens, Low Vision and
Visual Rehabilitation
Debra A. Thompson, Ph.D.
Vision Research
Susan S. Thoms, M.D.
Joshua P. Vrabec, M.D.
Jennifer S. Weizer, M.D.
Kwoon Y. Wong, Ph.D.
Vision Research
Maria A. Woodward, M.D.
Rebecca A. Wu, M.D.
Dongli Yang, M.D., Ph.D.
Vision Research
Retina and Uveitis
Linda Zhang, M.D.
Sergey N. Zolov, Ph.D.
Vision Research
Educating the next generation of ophthalmologists
and vision scientists
Our residents, clinical fellows, and research fellows
are an important part of the Kellogg community.
At Kellogg we are committed to bringing new
technologies and approaches to education to help
our graduates meet the challenges of changing
health care and research environments.
Graduate Chief Resident
Blake V. Fausett, M.D., Ph.D.
Lecturer, Comprehensive Ophthalmology and Cataract Surgery
M.D. University of Michigan
Ph.D. University of Michigan
1st Year Residents
David DeMill, M.D.
M.D. University of Utah
Neil Farbman, J.D., M.D.
J.D. Harvard University
M.D. University of Pennsylvania
Michelle Kron-Gray, M.D., Ph.D.
Ph.D. Neuroscience, University of
Michigan
Matthew Manry, M.D.
M.D. University of South Florida
Monica Michelotti, M.D.
Melisa Nika, M.D.
Andrew Stacey, M.S., M.D.
M.S. Brigham Young University
M.D. Ohio State University
3rd Year Residents
Nicholas D. Chinskey, M.D.
Abigail T. Fahim, M.D., Ph.D.
M.D. Baylor University
Stephen Smith, M.D.
M.D. Mayo Medical School
Ryan J. Fante, M.D.
M.D. University of Colorado Denver
Maxwell Stem, M.D.
M.D. Pennsylvania State University
Denise S. Kim, M.D.
Kevin Tozer, M.D.
M.D. University of Southern
California
Crandall E. Peeler, M.D.
M.D. Dartmouth College
Grace Wang, M.D., Ph.D.
M.D. Johns Hopkins University
Ph.D. Johns Hopkins University
2nd Year Residents
Courtney Kauh, M.D., M.S.
M.S. Ohio State University
M.D. University of Toledo
Mehnaz Khan, M.D., M.S.
M.S. Johns Hopkins University
M.D. Vanderbilt University
Lee Kiang, M.D., Ph.D.
M.D. Weill Cornell Medical College
Ph.D. The Rockefeller University
Patricia A. Ple-plakon, M.D.
Ira H. Schachar, M.D., M.Sc.
M.D. Washington University
M.Sc. Oxford University
Clinical Fellows
Alexandra Apkarian, M.D.
Adult Strabismus
Residency University of Michigan
Surbhi Bansal, M.D.
M.D. University at Buffalo
Residency University at Buffalo
Dane Breker, M.D.
Neuro-Ophthalmology
M.D. University of North Dakota
Michael Bullard, M.D.
Adult Strabismus
M.D. University of Iowa
Steven Cohen, M.D.
Vitreo-Retinal Surgical
M.D. University of MissouriKansas City
Residency University of Texas
Health Science Center
Angela Elam, M.D.
M.D. Duke University
Residency University of Pittsburgh
Joshua Grant, M.D.
Medical Retinal
M.D. Wayne State University
Residency University of South
Florida
Chirag Gupta, M.D.
Residency William Beaumont
Hospital
Lauren Harris, M.D.
M.D. University of Tennessee
Residency University of Tennessee
Nieraj Jain, M.D.
Vitreo-Retinal Surgical
M.D. Duke University
Residency Duke University
Allison N. McCoy, M.D., Ph.D.
M.D., Ph.D. Duke University
Residency Wilmer Eye Institute
Dolly Padovani-Claudio, M.D., Ph.D.
Adult Strabismus
M.D., Ph.D. Case Western Reserve
University
Fatemeh Rajaii, M.D., Ph.D.
M.D., Ph.D. Johns Hopkins
University
Residency Wilmer Eye Institute
Rashmi Verma, MS Ophth.
Neuro-Ophthalmology
MS Ophth. Regional Institute of
Ophthalmology, Gandhi Medical
College & Associated Hamidia
Hospital, Barkatullah University,
Bhopal (MP), India
Fellowship Pediatric Ophthalmology,
Akron Children’s Hospital
Research Fellows
Esther Gramage Caro, Ph.D.
Ph.D. Universidad San Pablo-CEU,
Madrid, Spain
Lisheng Chen, Ph.D.
Ph.D. Institute of Genetics and
Developmental Biology, Chinese
Academy of Sciences, Beijing,
China
Travis D’Cruz, Ph.D.
Ph.D. Pennsylvania State University
Jennifer Dulle, Ph.D.
Ph.D. Washington University
Edith Arnold Hernandez, Ph.D.
Ph.D. Universidad Autonoma de
San Luis Potosi, Mexico
Ryohsuke Kohmoto, M.D.
M.D. Osaka Medical College,
Osaka, Japan
Jason M. Miller, M.D., Ph.D.
M.D. University of California,
San Francisco
Ph.D. University of California,
San Francisco
Nupur Raychaudhuri, Ph.D.
Ph.D. Bose Institute, Calcutta, India
Shameka J. Shelby, Ph.D.
Benjamin K. Stafford, Ph.D.
Ph.D. University of California,
Santa Cruz
Scott M. Taylor, Ph.D.
Ph.D. Florida Institute of Technology
Alfonso Saera Vila, Ph.D.
Ph.D. University of Valencia,
Valencia, Spain
Xiwu Zhao, Ph.D.
Ph.D. Institute of Biophysics,
Chinese Academy of Sciences,
Beijing, China
W.K. Kellogg Eye Center Faculty, Fellows, and Residents 2013
All of us at the Kellogg Eye Center are
committed to improving lives through
curing, preventing, and treating eye
disease.
Faculty of the Department of
Ophthalmology and Visual Sciences
1st Row:
Thomas W. Gardner, M.D., M.S., Alan Sugar, M.D., Paul P. Lee, M.D., J.D.,
Shahzad I. Mian, M.D., Michael W. Smith-Wheelock, M.D.
2nd Row:
Naheed W. Khan, Ph.D., Jennifer A. Kozak, M.D., Jonathan D. Trobe, M.D.,
Sayoko E. Moroi, M.D., Ph.D., Donna M. Wicker, O.D., H. Kaz Soong, M.D.,
Adrienne L. West, M.D., Christine C. Nelson, M.D., Monte A. Del Monte, M.D.,
Mark W. Johnson, M.D., Jennifer S. Weizer, M.D., Denise S. Kim, M.D.,
Sherry H. Day, O.D., Allison N. McCoy, M.D., Ph.D.,
Kristen Harris Nwanyanwu, M.D., M.B.A
3rd Row:
Patricia A. Ple-plakon, M.D., Jeffrey M. Sundstrom, M.D., Ph.D.,
David C. Musch, Ph.D., M.P.H., Paul R. Lichter, M.D., Hakan Demirci, M.D.,
Frank W. Rozsa, Ph.D., Rebecca A. Wu, M.D., Kari Branham, M.S., C.G.C.,
Partho Satish Kalyani, M.D., Susan S. Thoms, M.D., Terry J. Bergstrom, M.D.,
Bret A. Hughes, Ph.D., Nieraj Jain, M.D., Joshua D. Stein, M.D., M.S.,
Courtney A. Dewey, O.D., Alon Kahana, M.D., Ph.D.
4th Row:
Courtney Kauh, M.S., M.D., S. Asha Balakrishnam, M.D.,
Ariane D. Kaplan, M.D., Shivani Gupta, M.D., M.P.H.,
Paula Anne Newman-Casey, M.D., M.S., Duna Raoof-Daneshvar, M.D.,
Joshua P. Vrabec, M.D., Brenda L. Bohnsack, M.D., Ph.D.,
Christopher T. Hood, M.D., Matthew Manry, M.D., César A. Briceño, M.D.,
Gale A. Oren, M.I.L.S., Denise A. John, M.D., Gary S. Sandall, M.D.,
Lindsey B. De Lott, M.D., Hilary M. Grabe, M.D., Theresa M. Cooney, M.D.,
Elizabeth Du, M.D., David A. Antonetti, Ph.D., Abigail T. Fahim, M.D., Ph.D.,
Lee Kiang, M.D., Ph.D.
5th Row:
Blake V. Fausett, M.D., Ph.D., Michael Bullard, M.D.,
Alexandra O. Apkarian, M.D., Monica Michelotti, M.D., Paul J. Grenier, O.D.,
Kwoon Y. Wong, Ph.D., Steven F. Abcouwer, Ph.D., Peter F. Hitchcock, Ph.D.,
Helios T. Leung, Ph.D., O.D., Carlton J. Foster, O.D., Amy L. Lagina, O.D.,
Wayne T. Cornblath, M.D., Nicholas D. Chinskey, M.D., Travis C. Rumery, M.D.,
Bruce A. Furr, C.O., Ph.D., Donald G. Puro, M.D., Ph.D., Cheng-mao Lin, Ph.D.,
Linda Zhang, M.D., Shreya S. Prabhu, M.D.
6th Row:
Ira H. Schachar, M.D., Stephanie Chu, M.D., Andrew Stacey, M.S., M.D.,
David N. Zacks, M.D., Ph.D., Ryan J. Fante, M.D., Crandall E. Peeler, M.D.,
Nadeem H. Fatteh, M.D., Philip J. Gage, Ph.D., Jonathan B. Greene, M.D.,
Christopher Gappy, M.D., Steven M. Archer, M.D., Arivalagan Muthusamy, Ph.D.,
Xuwen Liu, M.D., Ph.D., Karen S. DeLoss, O.D., Cagri G. Besirli, M.D., Ph.D.,
K. Thiran Jayasundera, M.D., Jerome I. Finkelstein, M.D.,
Bradley W. Taylor, O.D., M.P.H., Debra A. Thompson, Ph.D.,
John R. Heckenlively, M.D., Hemant S. Pawar, Ph.D.
Our guiding principles are teamwork,
caring, innovation, and integrity.
In 2013, the W.K. Kellogg Eye Center
was again named one of the top
ophthalmology programs in the country
by U.S. News and World Report.
Executive Officers of the University of Michigan Health System
Ora Hirsch Pescovitz, M.D.
Executive Vice President for Medical Affairs
Douglas L. Strong, M.B.A.
Chief Executive Officer, U-M Hospitals and Health Centers
James O. Woolliscroft, M.D.
Dean, U-M Medical School
The Regents of the University of Michigan
Mark J. Bernstein, Julia Donovan Darlow,
Laurence B. Deitch, Shauna Ryder Diggs, Denise Ilitch,
Andrea Fischer Newman, Andrew C. Richner,
Katherine E. White, Mary Sue Coleman (ex officio)
Editor: Betsy Nisbet
Writers: Aimee Bergquist, Barbara Sefton
Editorial Assistant: Lisa Burkhart
Design and Art Direction: David Murrel
Photographers: Eric Bronson, Roger Hart, Scott Soderberg,
Austin Thomason, Martin Vloet, Michigan Photography;
Lin Goings, U-M Department of Ophthalmology and
Visual Sciences
For patient questions, please call 734.763.8122
For additional copies, please contact us:
University of Michigan
Department of Ophthalmology and Visual Sciences
W.K. Kellogg Eye Center
1000 Wall Street
Ann Arbor, Michigan 48105
734.763.4660 • www.kellogg.umich.edu
How to Contact a Kellogg Doctor
Call the Kellogg Eye Center
To make an appointment, you can call the
clinic or our main line: 734.763.8122
734.764.4190
Contact Lens
734.764.5106
Call One of Our Community
Clinics for Comprehensive
and Specialty Care
Briarwood – 734.647.9000
Brighton – 810.227.2357
Canton – 734.844.5400
Chelsea – 734.475.1321
Cornea, External Disease,
734.764.5106
Eye Plastic, Orbital
and Facial Cosmetic Surgery
734.764.5106
Glaucoma and Cataract Surgery
734.763.5874
LASIK and other Refractive Surgery
734.615.6914
Low Vision and Visual Rehabilitation
734.764.5106
Neuro-Ophthalmology
734.764.5106
Ocular Oncology
734.763.5874
Livonia – 734.432.7811
Milford – 248.684.7337
Ypsilanti – 734.615.0788
Find More on the Web
Physician Bios:
www.kellogg.umich.edu/about/faculty_bios.html
Kellogg Research:
www.kellogg.umich.edu/research
Kellogg Clinics:
www.kellogg.umich.edu/patientcare/
specialties.html
For Our Referring Physicians
Make a referral or speak with a physician
734.764.7558
24 hours a day via M-LINE at 800.962.3555
Retina and Uveitis
734.763.5874
Jennifer Ziehm-Scott, Kellogg Physician Liaison, at
Thyroid Eye Disease Center
734.764.5106
Learn more about Patient Services
at Kellogg www.kellogg.umich.
edu/patientcare
If you have questions or concerns, please contact
734.615.8200
TEAMWORK
INTEGRITY
INNOVATION
CARING

2013 Annual Report - University of Michigan Kellogg Eye Center

Transcription

Similar documents

LASIK Surgery - Ridgedale Surgery Center

Cartwheel a thon - FairfaxGymnastics.net

saint john`s hospital - Hungarian Medical Care company for the

Ophthalmology Service - Monroe Veterinary Associates

CORNEA SympOSium - University of Illinois College of Medicine at

Pediatric Ophthalmology and Eye Center

Another amazing Congress - the Royal College of Ophthalmologists

INSIDE THIS EDITION We Are Family

Listing Flyer - Former Crusty`s Pizza

marKetplace - Kellogg Company